U.S. patent application number 14/559803 was filed with the patent office on 2015-04-02 for s-triazolyl alpha-mercapto acetanilides as inhibitors of hiv reverse transcriptase.
The applicant listed for this patent is Ardea Biosciences, Inc.. Invention is credited to Martha DE LA ROSA, Jean-Luc GIRARDET, Esmir GUNIC, Zhi HONG, Woo-Hong KIM, Yung-Hyo KOH, Stanley LANG.
Application Number | 20150094284 14/559803 |
Document ID | / |
Family ID | 36000576 |
Filed Date | 2015-04-02 |
United States Patent
Application |
20150094284 |
Kind Code |
A1 |
GIRARDET; Jean-Luc ; et
al. |
April 2, 2015 |
S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV
REVERSE TRANSCRIPTASE
Abstract
A series of S-triazolyl .alpha.-mercaptoacetanilides having
general structure (1) are provided, where Q is CO.sub.2H,
CONR.sub.2, SO.sub.3H, or SO.sub.2NR.sub.2. The compounds inhibit
several variants of the reverse transcriptase of HIV, and are
useful in the treatment of HIV infections. ##STR00001##
Inventors: |
GIRARDET; Jean-Luc; (San
Diego, CA) ; KOH; Yung-Hyo; (Irvine, CA) ; DE
LA ROSA; Martha; (Durham, NC) ; GUNIC; Esmir;
(San Diego, CA) ; HONG; Zhi; (Chapel Hill, NC)
; LANG; Stanley; (Concord Twp, OH) ; KIM;
Woo-Hong; (Cambridge, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Ardea Biosciences, Inc. |
San Diego |
CA |
US |
|
|
Family ID: |
36000576 |
Appl. No.: |
14/559803 |
Filed: |
December 3, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13081398 |
Apr 6, 2011 |
8946273 |
|
|
14559803 |
|
|
|
|
11661079 |
Mar 20, 2008 |
7947721 |
|
|
PCT/US05/30259 |
Aug 25, 2005 |
|
|
|
13081398 |
|
|
|
|
60686351 |
May 31, 2005 |
|
|
|
60604219 |
Aug 25, 2004 |
|
|
|
60604220 |
Aug 25, 2004 |
|
|
|
Current U.S.
Class: |
514/158 ;
514/326; 514/384; 544/132; 546/167; 546/210; 548/263.8 |
Current CPC
Class: |
A61P 31/00 20180101;
C07D 401/04 20130101; C07D 405/12 20130101; A61P 43/00 20180101;
A61P 31/18 20180101; C07D 401/12 20130101; C07D 249/12 20130101;
C07D 249/14 20130101 |
Class at
Publication: |
514/158 ;
548/263.8; 514/384; 544/132; 546/167; 546/210; 514/326 |
International
Class: |
C07D 249/12 20060101
C07D249/12; C07D 405/12 20060101 C07D405/12; C07D 401/12 20060101
C07D401/12; C07D 401/04 20060101 C07D401/04 |
Claims
1. A compound of formula A ##STR00325## wherein: Q is selected from
the group consisting of CO.sub.2H or a salt thereof, CONR'R'',
SO.sub.3H or a salt thereof, and SO.sub.2NR'R''; P is selected from
the group consisting of (a), (b), (c) and (d) ##STR00326## R.sup.1
is selected from the group consisting of Cl, Br, I, CH.sub.3,
CF.sub.3, CHF.sub.2, and CH.sub.2F; R.sup.3 is H or CH.sub.3; R'
and R'' are independently selected from the group consisting of H,
lower alkyl, and lower alkyl substituted with one or more OR,
CO.sub.2R, NHR, NR.sub.2, or CF.sub.3 groups wherein R is H or
lower alkyl, or R' and R'' together with the nitrogen atom to which
they are attached form a 4-, 5-, or 6-membered heterocyclic ring;
R.sup.0 is selected from the group consisting of Cl, Br, CF.sub.3
and methyl; R.sup.P is selected from the group consisting of
halogen, methyl, ethyl, propyl, isopropyl, cyclopropylmethyl, and
C.sub.3-C.sub.6 cycloalkyl; R.sup.4, R.sup.5 and R.sup.6 are
independently selected from the group consisting of H, F, Cl, Br,
CH.sub.3, CF.sub.3, CFH.sub.2, CF.sub.2H, isopropyl, cyclopropyl,
OCH.sub.3, OH, OCF.sub.3, NH.sub.2 and NHCH.sub.3; U and U' are
independently selected from N and CH; R.sup.7 is selected from the
group consisting of Cl, Br, I, CH.sub.3, CF.sub.3, OCH.sub.3,
isopropyl, cyclopropyl, tert-butyl, and cyclobutyl; and R.sup.8,
R.sup.9, R.sup.10 and R.sup.11 are independently H or CH.sub.3;
with the provisos that, when Q is SO.sub.2NH.sub.2, R.sup.1 is not
methyl unless R.sup.P is halogen, cyclopropylmethyl or
C.sub.3-C.sub.6 cycloalkyl, and R.sup.7 is methyl only if R.sup.6
is methyl.
2. The compound of claim 1, wherein none of R.sup.4, R.sup.5, and
R.sup.6 are OH, NH.sub.2 or NHCH.sub.3.
3. The compound of claim 1, wherein P is not substituted phenyl and
at least one of R.sup.4, R.sup.5, and R.sup.6 is other than H or
CH.sub.3.
4. The compound of claim 1, wherein P is a substituted phenyl and
R.sup.6 is not methyl.
5. The compound of claim 2, wherein P is not substituted phenyl and
at least one of R.sup.4, R.sup.5, and R.sup.6 is other than H or
CH.sub.3.
6. The compound of claim 3, wherein P is not substituted phenyl and
at least one of R.sup.4, R.sup.5, and R.sup.6 is other than H or
CH.sub.3.
7. The compound of claim 2, wherein P is a substituted naphthyl and
R.sup.1 is selected from the group consisting of Br, CF.sub.3,
CFH.sub.2, and CF.sub.2H.
8. The compound of claim 7, wherein each of R.sup.4, R.sup.5, and
R.sup.6 is H.
9. The compound of claim 7, wherein R.sup.P is cyclopropyl.
10. The compound of claim 7, wherein R.sup.1 is Br and R.sup.0 is
Cl.
11. The compound of claim 2, wherein P is a substituted quinoline
or isoquinoline and R.sup.1 is selected from the group consisting
of Br, CF.sub.3, CFH.sub.2, and CF.sub.2H.
12. The compound of claim 11, wherein each of R.sup.4, R.sup.5, and
R.sup.6 is H.
13. The compound of claim 11, wherein R.sup.P is cyclopropyl.
14. The compound of claim 11, wherein R.sup.1 is Br and R.sup.0 is
Cl.
15. The compound of any one of claims 3, 7, and 11, wherein Q is
SO.sub.2NH.sub.2.
16. The compound of any of claim 2, 4, 9 or 11 wherein Q is
CO.sub.2H.
17. The compound of claim 16, wherein the salt is Na.sup.+,
K.sup.+, Ca.sup.++, Mg.sup.++, or DABCO salt.
18. A pharmaceutical composition comprising a compound of any of
claims 1-17 in combination with one or more pharmaceutically
acceptable carriers.
19. A compound having a structure according to any one of Formula A
##STR00327## wherein R.sub.1 is C.sub.1-3 alkyl, --CF.sub.3,
--CHF.sub.2, --CH.sub.2F, --Cl, --Br, --NH.sub.2, or hydrogen;
R.sub.2 is an aryl or heteroaryl moiety containing a cycloalkyl or
heterocyclic group which can be further substituted with alkyl,
cycloalkyl, aryl or heteroaryl moieties, Q is a C.sub.3-5
cycloalkyl, W is S, O, or an optionally substituted amine; X and Y
are independently CH and N, and Z is, CH.sub.2, NH, NR, O, or S,
where R is optionally substituted N-alkyl, N-acyl, or N-alkyl-acyl;
R.sub.3 is C.sub.1-3 alkyl, --CF.sub.3, --CHF.sub.2, --CH.sub.2F,
--Cl, --Br; and R.sub.4 is COOH, --COR' or --S(O).sub.2R', wherein
R' is --NH.sub.2 or --NH(alkyl).
20. The compound of claim 20 wherein R.sub.2 is 4-Q-naphth-1-yl or
4-Q-phen-1-yl.
21. The compound of claim 20, wherein R' is NH.sub.2 and R.sub.4 is
other than COOH.
22. The compound of claim 21, wherein Q is cyclopropyl.
23. The compound of claim 21, wherein W is S.
24. The compound of claim 22, wherein W is S.
25. The compound of claim 24, wherein R.sub.1 is other than
hydrogen.
26. The compound of claim 25, wherein R.sub.1 is Br, R.sub.2 is
naphthyl, and R.sub.3 is methyl or Cl.
27. The compound of claim 26, which is
2-[5-bromo-4-(4-cyclopropyl-naphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfan-
yl]-N-(2-chloro-4-sulfamoyl-phenyl)-acetamide or
2-[5-bromo-4-(4-cyclopropyl-naphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfan-
yl]-N-(2-chloro-4-carbamoyl-phenyl)-acetamide.
28. The compound of claim 26, which is
2-[5-bromo-4-(4-cyclopropyl-naphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfan-
yl]-N-(2-methyl-4-sulfamoyl-phenyl)-acetamide or
2-[5-bromo-4-(4-cyclopropyl-naphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfan-
yl]-N-(2-methyl-4-carbamoyl-phenyl)-acetamide.
29. A compound of Formula A ##STR00328## wherein R.sub.1 is
C.sub.1-3 alkyl, --CF.sub.3, --CHF.sub.2, --CH.sub.2F, --Cl, --Br,
--NH.sub.2, or hydrogen; R.sub.2 is an 4-Q-naphth-1-yl or
4-Q-phen-1-yl-, Q is C.sub.2-5 alkyl, W is S, O or an optionally
substituted amine; R.sub.3 is C.sub.1-3 alkyl, --CF.sub.3,
--CHF.sub.2, --CH.sub.2F, --Cl, --Br; and wherein R.sub.4 is COOH,
--COR' or --S(O).sub.2R', wherein R' is --NH.sub.2 or
--NH(alkyl).
30. The compound of claim 30, where W is S.
31. The compound of claim 30, wherein R' is NH.sub.2 and R.sub.4 is
other than COOH.
32. The compound of claim 30, wherein R.sub.1 is other than H.
33. The compound of claim 32, wherein Q is ethyl.
34. The compound of claim 33, wherein R.sub.3 is chloro or
methyl.
35. The compound of claim 34, which is
2-[5-bromo-4-(4-ethyl-naphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfanyl]-N--
(2-chloro-4-sulfamoyl-phenyl)-acetamide or
2-[5-bromo-4-(4-ethyl-naphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfanyl]-N--
(2-chloro-4-carbamoyl-phenyl)-acetamide.
36. A compound of formula ##STR00329## wherein: P is selected from
the group consisting of (a), (b), (c) and (d): ##STR00330## R.sup.1
is selected from the group consisting of Cl, Br, I, CH.sub.3,
CF.sub.3, CHF.sub.2, and CH.sub.2F; R.sup.2, and R.sup.2' are
independently selected from the group consisting of H, optionally
substituted C.sub.1-5 acyl, 1-(C.sub.2-4 acyloxy)C.sub.1-4
alkoxycarbonyl, and an acyl group derived from an .alpha.-amino
acid; R.sup.3 is H or CH.sub.3; R.sup.0 is selected from the group
consisting of Cl, Br, CF.sub.3 and methyl; R.sup.P is selected from
the group consisting of methyl, ethyl, propyl, isopropyl,
cyclopropylmethyl, and C.sub.3-6 cycloalkyl; R.sup.4, R.sup.5 and
R.sup.6 are independently selected from the group consisting of H,
F, Cl, Br, CH.sub.3, CF.sub.3; CFH.sub.2, CF.sub.2H, isopropyl,
cyclopropyl, OCH.sub.3, OH, OCF.sub.3, NH.sub.2 and NHCH.sub.3; U
and U' are independently selected from N and CH; R.sup.7 is
selected from the group consisting of Cl, Br, I, CH.sub.3,
CF.sub.3, OCH.sub.3, isopropyl, cyclopropyl, tert-butyl,
cyclobutyl, and methyl; and R.sup.8, R.sup.9, R.sup.10 and R.sup.11
are independently H or CH.sub.3; with the provisos that, when
R.sup.2 and R.sup.2' are H, R.sup.1 is not methyl unless R.sup.P is
cyclopropyl, and R.sup.7 is methyl only if R.sup.6 is methyl.
37. The compound of claim 36, wherein none of R.sup.4, R.sup.5, and
R.sup.6 are OH, NH.sub.2 or NHCH.sub.3.
38. The compound of claim 36, wherein P is not substituted phenyl
and at least one of R.sup.4, R.sup.5, and R.sup.6 is other than H
or CH.sub.3.
39. The compound of claim 36, wherein P is a substituted phenyl and
R.sup.6 is not methyl.
40. The compound of claim 37, wherein P is not substituted phenyl
and at least one of R.sup.4, R.sup.5, and R.sup.6 is other than H
or CH.sub.3.
41. The compound of claim 38, wherein P is not substituted phenyl
and at least one of R.sup.4, R.sup.5, and R.sup.6 is other than H
or CH.sub.3.
42. The compound of claim 37, wherein Ar is a substituted naphthyl
and R.sub.1 is selected from the group consisting of Br, CF.sub.3,
CFH.sub.2, and CF.sub.2H.
43. The compound of claim 42, wherein each of R.sup.4, R.sup.5, and
R.sup.6 is H.
44. The compound of claim 42, wherein R.sup.P is cyclopropyl.
45. The compound of claim 42, wherein R.sup.1 is Br and R.sup.0 is
Cl.
46. The compound of claim 37, wherein P is a substituted quinoline
or isoquinoline and R.sup.1 is selected from the group consisting
of Br, CF.sub.3, CFH.sub.2, and CF.sub.2H.
47. The compound of claim 46, wherein each of R.sup.4, R.sup.5, and
R.sup.6 is H.
48. The compound of claim 46, wherein R.sup.P is cyclopropyl.
49. The compound of claim 46, wherein R.sup.1 is Br and R.sup.0 is
Cl.
50. The compound of claim 38, wherein R.sup.2 is acetyl or
2-acetyl-propoxycarbonyl.
51. The compound of claim 37, wherein R.sup.2 is acetyl or
1-acetoxyethoxycarbonyl.
52. The compound of claim 46, wherein R.sup.2 is acetyl or
1-acetoxyethoxycarbonyl.
53. The compound of any one of claims 50, 51 and 52, wherein
R.sup.2' is H.
54. The compound of any one of claims 38, 42, and 46, wherein
R.sup.2 and R.sup.2' are both H.
Description
RELATED APPLICATIONS
[0001] This application is a continuation patent application of
co-pending U.S. application Ser. No. 13/081,398, filed Apr. 6,
2011, which is a divisional application of U.S. application Ser.
No. 11/661,079, filed Mar. 20, 2008, and patented as U.S. Pat. No.
7,947,721 on May 24, 2011, which is the national phase entry of
international application PCT/US05/30259, filed Aug. 25, 2005,
which claims priority of U.S. provisional applications 60/604,219,
filed Aug. 25, 2004, 60/604,220, filed Aug. 25, 2004, and
60/686,351, filed May 31, 2005, the contents of each of which are
incorporated herein by reference in their entirety.
FIELD OF THE INVENTION
[0002] The field of the invention is enzyme inhibitors and the use
of enzyme inhibitors for treatment of disease. More particularly,
the invention deals with the in vitro and in vivo inhibition of HIV
reverse transcriptase as a method of treating HIV infection.
BACKGROUND OF THE INVENTION
[0003] Numerous treatments for HIV are known in the art, and among
other pharmaceutically active compounds, reverse transcriptase
inhibitors have provided significant therapeutic effect to many HIV
infected patients. For example, lamivudine (3TC) or zidovudine
(AZT) are relatively well tolerated antiretroviral drugs. However,
numerous viral strains have recently emerged with marked resistance
against these compounds. To overcome resistance to at least some
degree, new nucleoside-type inhibitors may be administered (alone
or in combination with other nucleoside-type inhibitors), and
exemplary alternative drugs include stavudine (d4T), didanosine
(ddl), Combivir.TM.(brand for a combination of lamivudine and
zidovudine), and Trizivir.TM. (brand for a combination of 3TC, AZT,
and abacavir).
[0004] Unfortunately, development of resistance to one
nucleoside-type inhibitor is often accompanied by the development
of a degree of resistance to another nucleoside-type inhibitor,
frequently necessitating a switch to a different class of drug. In
such cases, a patient may receive a protease inhibitor (e.g.,
saquinavir, indinavir, nelfinavir, etc.), typically in combination
with other anti retroviral agents. However, the relatively complex
administration regimen of such combinations often proves an
organizational and financial challenge to many patients, and
compliance is frequently less than desirable.
[0005] More recently, HIV treatment has focused on combination
therapies that involve the administration of nucleoside reverse
transcriptase inhibitors with protease inhibitors and with
non-nucleoside reverse transcriptase inhibitors, and triple
combinations of nucleoside reverse transcriptase inhibitors,
non-nucleoside reverse transcriptase inhibitors and protease
inhibitors. Unfortunately, combination therapies of protease
inhibitors with nucleoside reverse transcriptase inhibitors are
often poorly tolerated and frequently lead to premature termination
of the therapy. Therefore, most current combination treatments
include a combination of nucleoside reverse transcriptase
inhibitors and non-nucleoside reverse transcriptase inhibitors.
[0006] Non-nucleoside-type inhibitors (e.g., nevirapine,
delavirdine, and efavirenz) are a structurally inhomogeneous group
of compounds that are thought to bind in a non-nucleoside pocket of
the reverse transcriptases. They significantly increase antiviral
efficacy when co-administered with nucleoside-type inhibitors.
While the non-nucleoside-type inhibitors seem to provide a
promising new class of antiviral drugs, several disadvantages still
remain. The cost of currently-known non-nucleoside-type inhibitors
is relatively high, and a single mutation in the viral reverse
transcriptases can induce a cross resistance against a wide class
of non-nucleoside reverse transcriptase inhibitors. Therefore,
there is an urgent to provide new non-nucleoside reverse
transcriptase inhibitors that have potent antiviral effects,
particularly against HIV mutant strains that exhibit resistance
against currently-known non-nucleoside reverse transcriptase
inhibitors.
[0007] The HIV virus has a relatively high frequency of mutation,
which often leads to drug resistance to current treatments. Studies
have been carried out to identify the mutation spectrum in the RT
proteins of viruses isolated from patients who had failed therapies
involving at least one NNRTI, and the results showed that the
mutant K103N was the most predominant for patients taking
efavirenz, while Y181C was predominant for patients taking
nevirapine. Other single mutations included K101E, G190S/A/E and
Y188L/C. Some of the most prevalent double mutations in patients
failing efavirenz include K103N-P225H, K103N-V108I, K103N-K101Q,
K103N-L100I, K103N-F227L, V106I-Y188L, K103N-Y188L and K103N-G190A.
There is a need to provide new compositions and methods for the
inhibition of these and other mutant reverse transcriptases.
[0008] The present application is related to work previously
disclosed in commonly owned applications PCT/US02/26186, filed Aug.
23, 2002, unpublished, and PCT/US03/27433, filed Aug. 22, 2003,
which was published as WO 2004/030611 on Apr. 15, 2004. U.S. Pat.
No. 5,939,462 to Connell et al. discloses a large number of
substituted heterocycles, useful as NPY5 receptor antagonists, some
of which are S-triazolyl mercaptoacetanilides similar to general
structure 1 below. Simoneau et al., in international patent
publication WO 2004/050643, disclose tetrazoles and a few triazoles
having structures similar to those of the present invention, having
reverse transcriptase inhibitory activity.
BRIEF DESCRIPTION
[0009] The inventors have discovered that the reverse transcriptase
(RT) of HIV may be inhibited by a select class of S-triazolyl
.alpha.-mercaptoacetanilides represented by general structure 1.
Surprisingly, some of these compounds were able to inhibit various
mutated RTs, including K103N, Y181C and Y188L.
##STR00002##
[0010] In formula 1, R.sup.1 is halogen, lower alkyl, lower
alkenyl, or lower alkynyl, wherein the lower alkyl, lower alkenyl,
or lower alkynyl groups may optionally be substituted, preferably
with one or more halogens. R.sup.3 is H or methyl, and the
substituent R.sup.0 is H, halogen, CF.sub.3, lower alkoxy, or lower
alkylthio. Q is CO.sub.2H, SO.sub.3H, CONR'R'' or SO.sub.2NR'R'',
wherein R' and R'' are independently H, lower alkyl, or lower alkyl
substituted with one or more OR, CO.sub.2R, NHR, NR.sub.2, or
CF.sub.3 groups wherein R is H or lower alkyl, or R' and R''
together with the nitrogen atom to which they are attached form a
4-, 5-, or 6-membered heterocyclic ring. P is an aromatic or
heteroaromatic ring having substituents as described in more detail
below.
[0011] Accordingly, the present invention provides compounds that
inhibit HIV reverse transcriptase in vitro and in vivo. The
invention also provides pharmaceutical compositions comprising one
or more of the compounds of the invention, the use of compounds of
the invention for the preparation of pharmaceutical compositions
for treatment of HIV, and methods of treatment of a patient
infected with HIV by administration of a therapeutically effective
amount of one or more of the compounds of the invention or a
pharmaceutically acceptable salt thereof.
DETAILED DESCRIPTION
[0012] The term "alkyl" as used herein refers to a cyclic,
branched, or straight hydrocarbon radical in which all of the
carbon-carbon bonds are single bonds, and the term "lower alkyl"
refers to alkyl groups of one to ten carbon atoms. The term
"cycloalkyl" as used herein refers to a cyclic or polycyclic alkyl
group containing 3 to 15 carbons. A cycloalkyl group may comprise
multiple condensed rings in which one of the distal rings may be
aromatic (e.g., indan-2-yl, tetrahydronaphth-1-yl, etc.)
[0013] Similarly, the term "alkenyl" as used herein refers to a
cyclic, branched, or straight hydrocarbon radical in which one or
more of the carbon-carbon bonds is a double bond, and the term
"lower alkenyl" refers to alkenyl groups of one to ten carbon
atoms. The term "cycloalkenyl" as used herein refers to a cyclic or
polycyclic alkyl group containing 3 to 15 carbons, in which one or
more of the carbon-carbon bonds is a double bond. A cycloalkenyl
group may comprise multiple condensed rings in which one of the
distal rings may be aromatic (e.g., inden-2-yl,
1,2-dihydronaphth-1-yl, etc.)
[0014] Likewise, the term "alkynyl" as used herein refers to an
alkyl or alkenyl group, as defined above, in which at least one
carbon-carbon bond has been replaced by a triple bond. The term
"lower alkynyl" thus includes alkynyl groups with one to ten carbon
atoms.
[0015] As used herein, the term "alkoxy" refers to an --OR group,
wherein R is lower alkyl, lower alkenyl, lower alkynyl, aryl-lower
alkyl, heteroaryl-lower alkyl, or heterocyclo-lower alkyl.
Similarly, the term "aryloxy" refers to an --OAr group, wherein Ar
is an aryl or heteroaryl group.
[0016] The terms "aryl" and "Ar" are used interchangeably herein,
and refer to a monocyclic or polycyclic hydrocarbon group of 6 to
14 carbons, having at least one aromatic ring which provides the
point of attachment of the group. Polycyclic aryl groups may have
isolated rings (e.g. biphenyl) or condensed rings in which at least
one ring is aromatic, (e.g., 1,2,3,4-tetrahydronaphth-6-yl,
naphthyl, anthryl, or phenanthryl).
[0017] The terms "heterocycle" or "heterocyclic ring" are used
interchangeably herein and refer to a saturated, partially
unsaturated, or aromatic cycloalkyl or aryl group, having a single
ring (e.g., morpholino, pyridyl or furyl) or multiple condensed
rings (e.g., naphthyridyl, quinoxalinyl, quinolinyl, or
indolizinyl) in which at least one carbon atom in a ring has been
replaced by a heteroatom. The term "heteroatom" as used herein
refers to an atom other than carbon (typically S, O, P or N). The
terms "heteroaryl" and "heteroaromatic" refer to heterocycles in
which at least one heterocyclic ring is aromatic.
[0018] Still further, the term "optionally substituted" as used
herein means that one or more hydrogen atoms that are covalently
bound to a group or substituent as defined above, or a free
electron pair on a nitrogen or phosphorous atom, may be replaced by
a covalently-bound non-hydrogen substituent selected from the group
consisting of R, Ar, aryl-lower alkyl, OH, SH, OR, SR, OAr, SAr,
S(.dbd.O)R, S(.dbd.O)Ar, SO.sub.2R, SO.sub.2Ar, halogen, CF.sub.3,
OCF.sub.3, SCF.sub.3, NH.sub.2, NHR, NR.sub.2, NR.sub.3+, NHCOR,
NHCOAr, NHS(.dbd.O)R, NHS(.dbd.O)Ar, NHSO.sub.2R, NHSO.sub.2Ar,
NO.sub.2, CN, CO.sub.2R, CONH.sub.2, CONHR, CONR.sub.2, C(.dbd.O)R,
heteroaryl, and heteroaryl-lower alkyl. In the above substituents,
R is lower alkyl, lower alkenyl, lower alkynyl, aryl-lower alkyl,
heteroaryl-lower alkyl, or heterocyclyl-lower alkyl.
[0019] The term "prodrug" as used herein refers to a modification
of a compound of the invention, wherein the modified compound
exhibits less pharmacological activity (as compared to the
unmodified compound) and wherein the modified compound is converted
back into the unmodified form in vivo, preferably within a target
cell (e.g., a T-cell or hepatocyte) or a target organ (e.g., lymph
node or spleen). Conversion of a compound of the invention into a
prodrug form may be useful where the active drug is too toxic for
safe systemic administration, where the unmodified compound is
poorly absorbed from the digestive tract, or where the body tends
to break down the unmodified compound before it reaches its
target.
[0020] The term "inhibiting a reverse transcriptase" refers to a
direct or indirect reduction in the formation of DNA from a
template RNA or DNA by a reverse transcriptase. Direct inhibition
includes suicide, competitive and non-competitive inhibition,
allosteric inhibition, or binding of an inhibitor in a
non-nucleoside pocket. Examples of indirect inhibition include
depletion of nucleosides for DNA synthesis, induction or
contribution to conformational changes, etc.
[0021] As used herein, the term "reducing viral propagation" means
that the titer of a virus in a sample is lowered. The reduction may
be effected in a variety of manners, including partial or total
inhibition of viral replication, partial or total inhibition of
viral protein processing or assembly, inhibition of viral entry
into or exit from an infected cell, and/or clearance of the virus
from a system via an immune response to the virus.
[0022] The invention provides, inter alia, compounds of the
following structure:
##STR00003##
wherein P, Q, R.sup.1, R.sup.3 and R.sup.0 are as defined above. In
preferred embodiments, R.sup.1 is selected from among Cl, Br, I,
CH.sub.3, CF.sub.3, CHF.sub.2, and CH.sub.2F; R.sup.3 is H; R.sup.0
is selected from among Cl, Br, CF.sub.3 and CH.sub.3; and Q is CO2H
or SO.sub.2NH.sub.2. In particularly preferred embodiments, R.sup.0
is Cl.
[0023] P is preferably a substituted phenyl, naphthyl,
1,2,3,4-tetrahydronaphthyl, quinolinyl, isoquinolinyl, or
cinnolinyl ring. In preferred embodiments, the group P is selected
from among the moieties (a), (b), (c) and (d) below:
##STR00004##
wherein R.sup.P is selected from among methyl, ethyl, propyl,
isopropyl, cyclopropylmethyl, or C.sub.3-6 cycloalkyl; R.sup.4,
R.sup.5 and R.sup.6 are independently selected from among H, F, Cl,
Br, CH.sub.3, CF.sub.3, CFH.sub.2, CF.sub.2H, isopropyl,
cyclopropyl, OCH.sub.3, OH, OCF.sub.3, NH.sub.2 and NHCH.sub.3.
[0024] U and U' are independently selected from N and CH; R.sup.7
is selected from among Cl, Br, I, CH.sub.3, CF.sub.3, OCH.sub.3,
isopropyl, cyclopropyl, t-butyl, and cyclobutyl; and
R.sup.8-R.sup.11 are independently H or CH.sub.3. Preferably, when
Q is SO.sub.2NH.sub.2, R.sup.1 is not methyl unless R.sup.P is
cyclopropyl or cyclopropylmethyl, and R.sup.7 is methyl only when
R.sup.6 is also methyl.
[0025] Preferred classes of compounds are those having Structures 2
and 3 below:
##STR00005##
wherein R.sup.1 is CF.sub.3, CHF.sub.2, CH.sub.2F, or halogen;
R.sup.0 is halogen, CF.sub.3 or methyl, R' and R'' are
independently H or an optionally substituted lower alkyl, C.sub.1-5
acyl, or 1-(C.sub.2-4 acyloxy)C.sub.1-4 alkoxyccarbonyl group, and
R.sup.P is as defined above.
[0026] Particularly preferred classes of compounds correspond to
structures 4 and 5
##STR00006##
where R.sup.P is selected from methyl, ethyl, propyl, isopropyl,
cyclopropyl, and cyclopropyl-methyl. It is most preferred that
R.sup.P is ethyl or cyclopropyl. Compounds combining the features
R.sup.1=Br, R.sup.0=Cl or CH.sub.3, P=naphthyl or
tetrahydronaphthyl, and Q=CO.sub.2H or SO.sub.2NR'R'' exhibit
surprisingly potent activity against RTs from a number of HIV
isolates, combined with unexpectedly good pharmacokinetics in
vivo.
Synthesis of Compounds
[0027] Synthesis of the compounds of the invention may be performed
following procedures substantially as described in WO 2004/030611,
WO 2004/050643, and U.S. Pat. No. 5,939,462. It should be
recognized, however, that numerous alternative synthetic routes for
the compounds of the invention are possible. The following
exemplary routes are provided by way of example, for the guidance
of practitioners skilled in the art of synthetic organic
chemistry.
[0028] In one synthetic route, a suitably substituted aniline is
amidated with an activated carboxylic acid compound (preferably a
carbonyl halide), wherein the activated carboxylic acid compound
further includes a leaving group L.sub.2 (preferably bromine).
After formation of the anilide, the reaction product is reacted
with a mercaptotriazole (Het-SH), displacing the leaving group to
form the desired compound as depicted in Scheme 1a below.
##STR00007##
[0029] This scheme is advantageous where the mercaptotriazole
"Het-SH" is valuable relative to the aniline, since the triazole is
not used until the last step and is not subjected to the inevitable
losses that occur during the synthetic manipulation of
intermediates. The choice of leaving groups L.sup.1 and L.sup.2
will depend to some extent on the particular choice of amine and to
a lesser degree on the particular mercaptotriazole. It is
particularly preferred that L.sup.1 and L.sup.2 are halide, most
preferably chloride or bromide. Suitable solvents for the amidation
reaction include ethers, alcohols, and hydrocarbons (preferably
halogenated) and the choice of suitable solvents will at least in
part depend on the chemical nature of the reactants. With respect
to the solvents, catalysts and/or bases employed in the above
reaction, the considerations described by Connell et al. (U.S. Pat.
No. 5,939,462) will generally apply.
[0030] An alternative general strategy is shown in Scheme 1b below.
This approach involves the acylation of anilines with S-triazoly
mercaptoacetic acids, which are readily prepared by alkylation of
mercaptotriazoles with an .alpha.-haloacetic acid or ester.
##STR00008##
[0031] Suitable reagents include but are not limited to iodoacetic
acid and methyl bromoacetate, and ethyl .alpha.-bromopropionate
when it is desired that R.sup.3 be methyl. If an ester is used, it
is hydrolyzed after the S-alkylation to provide a free carboxylic
acid. The acid and the aniline may be coupled with any of the usual
carboxyl activating reagents or reagent mixtures, for example a
carbodiimide in the presence of a tertiary amine base, optionally
with N-hydroxybenzotriazole as catalyst, or thionyl or oxalyl
chloride, with dimethylaminopyridine as catalyst. This scheme is
advantageous when the aniline is valuable relative to the
triazole.
[0032] An example of Scheme 1a is the synthesis outlined in Scheme
2, in which a compound of the invention is prepared from two
separately-prepared precursors. The first precursor, comprising a
substituted triazine, and the second precursor, comprising a
substituted aniline, may be prepared following the protocols given
below in the section entitled "Examples". Reaction of the
precursors is typically carried out in a polar aprotic solvent such
as DMF, in the presence of a base such as potassium carbonate.
##STR00009##
[0033] Where the triazine is substituted with a fluorinated alkyl
group, a synthetic procedure as shown in Scheme 3 may be employed.
A similar procedure is given below in the section entitled
"Examples".
##STR00010##
[0034] A halogen-substituted triazole may be prepared by
dihalogenation of a triazole, followed by displacement of one of
the halides, as shown in Scheme 4, which follows a procedure given
below in the section entitled "Examples".
##STR00011##
[0035] Another way to build a substituted triazole with a halogen
is by diazotization of an aminotriazole, as shown in Scheme 5
below, which follows a procedure given below in the section
entitled "Examples".
##STR00012##
[0036] Alternatively, where the triazole is substituted with a
CF.sub.3, the synthetic procedure shown in Scheme 6 may be
employed, following similar procedures given below in the section
entitled "Examples".
##STR00013##
[0037] An example of the alternate synthetic approach outlined in
Scheme 1a is shown in Scheme 7 below, wherein an aniline is
acylated by a preformed S-triazolyl mercapto-acetic acid.
##STR00014##
Pharmaceutical Compositions
[0038] Where compounds of the invention are administered as part of
a pharmacological composition, it is contemplated that suitable
compounds can be formulated in admixture with pharmaceutically
acceptable carriers, excipients, and other additives. It is
particularly preferred that the compounds of the invention are
included in a pharmaceutical composition that is formulated with
one or more non-toxic pharmaceutically acceptable carriers. The
pharmaceutical compositions may be formulated for oral
administration in solid or liquid form, for parenteral injection,
or for rectal administration.
[0039] The pharmaceutical compositions of this invention can be
administered to humans and other animals orally, rectally,
parenterally, intravaginally, intraperitoneally, topically,
bucally, or as an oral or nasal spray. The term "parenteral"
administration as used herein refers to modes of administration
which include but are not limited to intravenous, intramuscular,
intraperitoneal, subcutaneous and intra-articular injection and
infusion.
[0040] Pharmaceutical compositions for parenteral injection
preferably comprise pharmaceutically acceptable sterile aqueous or
nonaqueous solutions, dispersions, suspensions or emulsions as well
as sterile powders for reconstitution into sterile injectable
solutions or dispersions just prior to use. Examples of suitable
aqueous and nonaqueous carriers, diluents, solvents and vehicles
include water, ethanol, polyols (such as glycerol, propylene
glycol, polyethylene glycol, and the like), and suitable mixtures
thereof, vegetable oils (such as olive oil), and injectable organic
esters such as ethyl oleate. Proper fluidity can be maintained, for
example, by the use of coating materials such as lecithin, by the
maintenance of the required particle size in the case of
dispersions, and by the use of surfactants.
[0041] Compositions may also contain additives such as
preservatives, wetting agents, emulsifying agents, and dispersing
agents. Prevention of the action of microorganisms may be ensured
by the inclusion of various antibacterial and antifungal agents,
for example, paraben, chlorobutanol, phenol sorbic acid, and the
like. It may also be desirable to include isotonic agents such as
sugars, sodium chloride, and the like. Prolonged absorption of the
injectable pharmaceutical form may be brought about by the
inclusion of agents which delay absorption such as aluminum
monostearate and gelatin.
[0042] In order to prolong the effect of a compound of the
invention, it may be desirable to slow the absorption of the drug
from subcutaneous or intramuscular injection. This may be
accomplished by the use of a liquid suspension of crystalline or
amorphous material with poor water solubility. The rate of
absorption of the compound then depends upon its rate of
dissolution, which in turn may depend upon crystal size and
crystalline form. Alternatively, delayed absorption of a
parenterally-administered compound of the invention may be
accomplished by dissolving or suspending the drug in an oil
vehicle.
[0043] Injectable depot forms are made by forming unitary or
microparticulate matrices of a compound of the invention in
biodegradable polymers, including but not limited to
polylactide-polyglycolide, poly(orthoesters), and poly(anhydrides).
The rate of drug release can be controlled by varying the ratio of
drug to polymer and the nature of the particular polymer employed.
Depot injectable formulations may also prepared by entrapping the
compound in liposomes or microemulsions which are compatible with
body tissues.
[0044] Solid dosage forms for oral administration include but are
not limited to capsules, tablets, pills, powders, dragees, and
granules. In such solid dosage forms, the active compound is mixed
with at least one inert, pharmaceutically acceptable excipient or
carrier such as sodium citrate or dicalcium phosphate and/or (a)
fillers or extenders, such as starches, lactose, sucrose, glucose,
mannitol, and silicic acid, (b) binders, such as
carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone,
sucrose, and acacia, (c) humectants, such as glycerol, (d)
disintegrating agents, such as agar-agar, calcium carbonate, potato
or tapioca starch, alginic acid, certain silicates, and sodium
carbonate, (e) solution retarding agents, such as paraffin, (f)
absorption accelerators, such as quaternary ammonium compounds, (g)
wetting agents, such as cetyl alcohol and glycerol monostearate,
(h) absorbents, such as kaolin and bentonite clay, and (i)
lubricants, such as talc, calcium stearate, magnesium stearate,
solid polyethylene glycols, sodium lauryl sulfate, and mixtures
thereof. Solid dosage forms may also comprise buffering agents.
[0045] Solid compositions may also be employed as fillers in soft
and hard-filled gelatin capsules using such excipients as lactose
or milk sugar as well as high molecular weight polyethylene glycols
and the like. The solid dosage forms can be prepared with coatings
and shells such as enteric coatings and other coatings well-known
in the pharmaceutical formulating art. They may optionally contain
opacifying agents and may also be of a composition such that they
release the active ingredient(s) only, or preferentially, in a
certain part of the intestinal tract, optionally in a delayed
manner. The active compounds may also be in micro-encapsulated
form.
[0046] Liquid dosage forms for oral administration include
pharmaceutically acceptable emulsions, solutions, suspensions,
syrups and elixirs. In addition to the active compounds, the liquid
dosage forms may contain inert diluents commonly used in the art
such as, water or other solvents, solubilizing agents and
emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor, and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene
glycols and fatty acid esters of sorbitan, and mixtures thereof.
Oral liquid compositions may also include adjuvants such as wetting
agents, emulsifying and suspending agents, coloring, sweetening,
flavoring, and perfuming agents.
[0047] Compositions for rectal or vaginal administration are
preferably suppositories which can be prepared by mixing the
compounds of this invention with suitable non-irritating excipients
or carriers such as cocoa butter, polyethylene glycol or other
suppository waxes which are solid at room temperature but liquid at
body temperature and therefore melt in the rectum or vaginal cavity
and release the active compound.
[0048] Compounds of the present invention can also be administered
in the form of liposomes. As is known in the art, liposomes are
generally derived from phospholipids or other lipid substances.
Liposomes are typically formed from mono- or multi-lamellar
hydrated liquid crystals that are dispersed in an aqueous medium.
Any non-toxic, physiologically acceptable lipid capable of forming
liposomes may be used. Compositions in liposome form may contain,
in addition to a compound of the present invention, membrane
stabilizers, preservatives, excipients, and the like. The preferred
lipids are phospholipids and phosphatidyl cholines (lecithins),
both natural and synthetic. Methods to form liposomes are known in
the art. See, for example, Prescott, Ed., Methods in Cell Biology,
Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et
seq.
[0049] The compounds of the present invention may be used in the
form of pharmaceutically acceptable salts derived from inorganic or
organic acids. By "pharmaceutically acceptable salt" is meant those
salts which are, within the scope of sound medical judgment,
suitable for use in contact with the tissues of humans and lower
animals without undue toxicity, irritation, allergic response and
the like and are commensurate with a reasonable benefit/risk ratio.
Pharmaceutically acceptable salts are well-known in the art. For
example, S. M. Berge, et al. describe pharmaceutically acceptable
salts in detail in J. Pharmaceutical Sciences, 1977, 66:1 et seq.
The salts may be prepared in situ during the final isolation and
purification of the compounds of the invention or separately by
reacting a free base form with a suitable acid. Representative acid
addition salts include, but are not limited to acetate, adipate,
alginate, citrate, aspartate, benzoate, benzenesulfonate,
bisulfate, butyrate, camphorate, camphorsulfonate, citrate,
gluconate, glutamate, glycerophosphate, hemisulfate, heptanoate,
hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide,
2-hydroxyethansulfonate (isethionate), lactate, maleate,
methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate,
pamoate, pectinate, 3-phenylpropionate, phosphate, pivalate,
propionate, succinate, sulfate, tartrate, bicarbonate,
p-toluenesulfonate and undecanoate. Basic nitrogen-containing
groups may also be quaternized with such agents as lower alkyl
halides such as methyl, ethyl, propyl, and butyl chlorides,
bromides and iodides; dialkyl sulfates like dimethyl, diethyl,
dibutyl and diamyl sulfates; long chain halides such as decyl,
lauryl, myristyl and stearyl chlorides, bromides and iodides;
arylalkyl halides like benzyl and phenethyl bromides and others.
Water or oil-soluble or dispersible products are thereby
obtained.
[0050] Basic addition salts can be prepared in situ during the
final isolation and purification of compounds of this invention, or
subsequently, by reacting a carboxylic acid-containing moiety with
a suitable base such as the hydroxide, carbonate or bicarbonate of
a pharmaceutically acceptable metal cation or with ammonia or an
organic primary, secondary or tertiary amine. Pharmaceutically
acceptable salts include, but are not limited to, alkali and
alkaline earth metals such as lithium, sodium, potassium, calcium,
magnesium and aluminum salts and the like, and nontoxic quaternary
ammonium and amine salts including ammonium, tetramethylammonium,
tetraethylammonium, methylamine, dimethylamine, trimethylamine,
triethylamine, diethylamine, ethylamine and the like. Other
representative organic amines useful for the formation of base
addition salts include ethylenediamine, ethanolamine,
diethanolamine, piperidine, piperazine, glucosamine, leucine, and
the like.
[0051] Actual dosage levels of active ingredients in the
pharmaceutical compositions of this invention may be varied so as
to obtain an amount of the active compound(s) that is effective to
achieve the desired therapeutic response for a particular patient,
composition, and mode of administration. The selected dosage level
will depend upon the activity of the particular compound, the route
of administration, the dosing schedule, the severity of the
condition being treated, and the condition and prior medical
history of the patient being treated. Dose-ranging studies are
routine, and it is within the ability of those skilled in the art
to start doses of the compound at levels lower than required to
achieve the desired therapeutic effect and to gradually increase
the dosage until the desired effect is achieved. Generally, dosage
levels of about 0.1 to about 100, more preferably about 5 to about
50 mg of an active compound per kilogram of body weight per day are
administered orally to a mammalian patient. If desired, the
effective daily dose may be divided into multiple doses for
purposes of administration, e.g., two to four separate doses per
day.
[0052] The compounds of the invention may be administered alone or
in combination with other agents for the treatment of HIV.
Particularly contemplated additional compounds include
nucleoside-type reverse transcriptase inhibitors (e.g., lamivudine,
zidovudine, stavudine, abacavir, tenofovir or didanosine),
non-nucleoside reverse transcriptase inhibitors (e.g., nevirapine,
delavirdine, efavirenz), protease inhibitors (e.g., ritonavir,
saquinavir, indinavir, nelfinavir), fusion inhibitors (e.g.,
enfuvirtide), CCR5 antagonists, immunotherapeutic agents (e.g.,
ribavirin, IL-2), and active, passive, and/or therapeutic vaccines.
Combination therapies according to the present invention comprise
the administration of at least one compound of the present
invention or a functional derivative thereof and at least one other
pharmaceutically active ingredient. The active ingredient(s) and
pharmaceutically active agents may be administered separately or
together and when administered separately this may occur
simultaneously or separately in any order. The amounts of the
active ingredient(s) and pharmaceutically active agent(s) and the
relative timings of administration will be selected in order to
achieve the desired combined therapeutic effect.
[0053] Therefore, the present invention provides pharmaceutical
compositions comprising one or more compound having a structure
according to any of formulae 1-5, as defined above, wherein the
compound or compounds are present in a concentration effective to
inhibit a reverse transcriptase and/or HIV replication in a cell of
a patient when the composition is administered to the patient. In
preferred embodiments, the pharmaceutical composition of the
invention comprises one or more compounds according to any of
formulae 2-5. It is particularly contemplated that a plurality of
compounds may be incorporated into a single pharmaceutical
composition, in order to obtain wide-ranging inhibition of a
plurality of mutant RT enzymes.
[0054] With respect to suitable concentrations of contemplated
compounds in pharmaceutical compositions, it should be appreciated
that a person of ordinary skill in the art can readily adjust the
amount of the compound to achieve inhibition of the reverse
transcriptase and/or HIV replication. For example, inhibition of
the HIV replication in a cell (typically a T-cell infected with the
HIV virus) may be monitored in vitro using a blood culture and a
luciferase based assay system as described below. Alternatively,
inhibition of the reverse transcriptase may be monitored in vivo
using RT-PCR to determine the amount of copies of viral DNA and/or
RNA in blood or lymph nodes (containing HIV infected cells). It is
generally contemplated that suitable concentrations will achieve a
serum concentration of between 1 nM and 100 uM, and in some cases
between 0.01 nM and 1 nM).
EXAMPLES
[0055] The following experiments are provided only by way of
example, and should not be understood as limiting the scope of the
invention.
Compounds of the Invention
2-[5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfanyl-
]-N-(2-chloro-4-sulfamoylphenyl)acetamide (Method A)
##STR00015##
[0056] 1-Cyclopropyl-naphthalene
[0057] Cyclopropylmagnesium bromide (150 mL, 0.5 M in
tetrahydrofuran) was slowly added to a solution of
1-bromo-naphthalene (10 g, 50 mmol) and
[1,3-bis(diphenylphosphino)propane]dichloronickel(II) in
tetrahydrofuran (10 mL) stirred at 0.degree. C. The reaction
mixture was stirred at room temperature for 16 hours and the
solvent was evaporated under reduced pressure. EtOAc and ammonium
chloride in water were added. After extraction, the organic layer
was dried over sodium sulfate, filtered and concentrated under
reduced pressure. The residue was purified by silica gel
chromatography to yield 1-cyclopropyl-naphthalene (6.4 g, 76%).
1-Cyclopropyl-4-nitro-naphthalene
[0058] Sodium nitrite (30 mL) was slowly added (over 2 hours) to
1-cyclopropyl-naphthalene (6.4 g, 38 mmol) stirred at 0.degree. C.
The reaction mixture was stirred at 0.degree. C. for an extra 30
min and then was slowly poured into ice. Water was added, followed
by EtOAc. After extraction, the organic layer was washed with a 1%
aqueous solution of NaOH, then washed with water, dried over sodium
sulfate, filtered and concentrated under reduced pressure. The
residue was purified by silica gel chromatography to yield
1-cyclopropyl-4-nitro-naphthalene (5.2 g, 64%).
1-Amino-4-cyclopropyl-naphthalene
[0059] A solution of 1-cyclopropyl-4-nitro-naphthalene (5 g, 23
mmol) in ethanol (200 mL) was stirred under hydrogen in the
presence of Pd/C (10% net, 1.8 g). The reaction mixture was shaken
overnight, then filtered over celite. The solvent was evaporated,
and the residue was purified by silica gel chromatography to yield
1-amino-4-cyclopropyl-naphthalene (3.1 g, 73%).
1-Cyclopropyl-4-isothiocyanato-naphthalene
[0060] Thiophosgene (1.1 g, 9.7 mmol) was added to a solution of
1-amino-4-cyclopropyl-naphthalene (1.8 g, 9.7 mmol) and
diisopropylethylamine (2 eq) in dichloromethane (50 mL) stirred at
0.degree. C. The reaction mixture was stirred for 5 min at this
temperature, then a 1% solution of HCl in water was added and the
organic layer was separated, washed with brine, dried over sodium
sulfate, filtered and the solvent was evaporated under reduced
pressure. Hexane was added, and the resulting precipitate was
filtered. The solvent was evaporated to yield
1-cyclopropyl-4-isothiocyanatonaphthalene (1.88 g, 86%).
5-Amino-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]triazole-3-thiol
[0061] A mixture of aminoguanidine hydrochloride (3.18 g, 29 mmol),
1-cyclopropyl-4-isothiocyanato-naphthalene (3.24 g, 14 mmol) and
diisopropylethylamine (3 eq) in DMF (20 mL) was stirred at
50.degree. C. for 15 hours. The solvent was evaporated, toluene was
added, and the solvent was evaporated again. A 2.0 M aqueous
solution of sodium hydroxide (30 mL) was added and the reaction
mixture was heated at 50.degree. C. for 60 hours. The reaction
mixture was filtered, and the filtrate was neutralized with a 2.0 M
aqueous solution of HCl. New filtration, then evaporation of
solvent and purification of the residue by silica gel
chromatography to yield
5-amino-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]triazole-3-thiol
(2.0 g, 49%).
2-[5-Amino-4-(4-cyclopropylnaphthalen-1-yl-4H-[1,2,4]triazol-3-ylsulfanyl)-
-N-(2-chloro-4-sulfamoylphenyl)Acetamide
[0062] In a solution of
5-amino-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]triazole-3-thiol
(708 mg, 2.5 mmol), K.sub.2CO.sub.3 (380 mg, 2.5 mmol) in DMF (20
mL) was added 2-chloro-N-(2-chloro-4-sulfamoylphenyl)acetamide (710
mg, 2.5 mmol). The reaction mixture was stirred at room temperature
overnight. Upon completion of the reaction, the solvent was
evaporated. The residue was purified by silica gel chromatography
to yield
2-[5-Amino-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfany-
l]-N-(2-chloro-4-sulfamoylphenyl)acetamide (1.26 g, 95%).
2-[5-Bromo-4-(4-cyclopropylnaphthalen-1-yl]-4H-[1,2,4]triazol-3-ylsulfanny-
l]-N-(2-chloro-4-sulfamoylphenyl)acetamide
[0063] Dichloroacetic acid (180 uL, 2.2 mmol) was added to a
suspension of
2-[5-amino-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfany-
l]-N-(2-chloro-4-sulfamoylphenyl)acetamide (0.59 g, 1.1 mmol),
sodium nitrite (1.5 g, 22 mmol) and BTEABr (0.91 g, 3.3 mmol) in
dibromomethane (30 mL). The reaction mixture was stirred at room
temperature for 4 hours, then extracted with dichloromethane and
sodium bicarbonate in water. The organic layer was dried over
sodium sulfate, filtered and concentrated under reduced pressure.
The residue was purified by silica gel chromatography to yield
2-[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfany-
l]-N-(2-chloro-4-sulfamoylphenyl)acetamide (224 mg, 31%).
2-[5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]triazole-3-ylsulfany-
l]-N-(2-chloro-4-sulfamoylphenyl)acetamide (Method B)
##STR00016##
[0064]
2-[5-Amino-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]triazol-3-yls-
ulfanyl]acetic acid methyl ester
TABLE-US-00001 [0065] Materials Amount Mol. Wt. mmoles thiotriazole
2.24 g 282.36 7.9 methyl chloroacetate 0.73 ml 108.52 8.3 (1.05 eq)
potassium carbonate 1.21 g 138.21 8.7 (1.1 eq) dimethylformamide 40
ml (5 mL/mmol)
Procedure:
[0066] To a suspension of thiotriazole and potassium carbonate in
DMF was added methyl chloroacetate dropwise at room temperature for
5 min. The reaction was stirred at room temperature for 24 h and
slowly poured into a stirred ice-cold water solution. The tan
precipitate was collected by vacuum filtration and dried under high
vacuum at 50.degree. C. for 16 h in the presence of P.sub.2O.sub.5
to yield 2.24 g (80%) of the title compound.
2-[5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfanyl-
]acetic acid methyl ester
TABLE-US-00002 [0067] Materials Amount Mol. Wt. mmoles thiotriazole
L10183-58 709 mg 354.43 2.0 bromoform 10 ml (5 ml/mmol) sodium
nitrite 2.76 g 69.00 40 (20 eq) benzyltriethylammonium 1.63 g
272.24 6.0 (3 eq) bromide dichloroacetic acid 0.33 ml 128.94 4.0 (2
eq)
Procedure:
[0068] To a solution of
2-[5-amino-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfany-
l]acetic acid methyl ester and benzyltriethylammonium chloride in
bromoform was added sodium nitrite. To the mixture was added
dichloroacetic acid and the reaction mixture was stirred at room
temperature for 3 h. The mixture was directly loaded onto a 7-inch
column of silica gel that was packed with CH.sub.2Cl.sub.2. The
column was first eluted with CH.sub.2Cl.sub.2 until all CHBr.sub.3
eluted, and was then eluted with acetone/CH.sub.2Cl.sub.2 (5:95) to
give 713 mg (85%) of the title compound.
2-[5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfanyl-
]acetic acid
TABLE-US-00003 [0069] Materials Amount Mol. Wt. mmoles thiotriazole
methyl ester 1.14 g 418.31 2.7 tetrahydrofuran 10 ml (~3 ml/mmol)
ethanol 10 ml (~3 ml/mmol) water 10 ml (~3 ml/mmol) lithium
hydroxide 98 mg 23.95 4.1 (1.5 eq)
Procedure:
[0070] To a solution of
2-[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfany-
l]acetic acid methyl ester, in a mixture of THF and EtOH at
0.degree. C., was added a solution of LiOH in H.sub.2O dropwise
over 5 min. The reaction was complete after stirring at 0.degree.
C. for an additional 45 min. The reaction was neutralized to pH 7
by the addition of 0.5 N HCl solution at 0.degree. C., and the
resulting mixture was concentrated in vacuo to 1/5th of its
original volume. The mixture was diluted with H.sub.2O (.about.20
mL) and acidified to pH 2-3 by the addition of 0.5 N HCl to produce
sticky solid. (If the product comes out as an oil during
acidification, extraction with CH.sub.2Cl.sub.2 is recommended.)
The tan solid was collected by vacuum filtration and dried under
high vacuum at 50.degree. C. for 16 h in the presence of
P.sub.2O.sub.5 to yield 1.02 g (93%) of the title compound.
2-[5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]-triazole-3-ylsulfan-
yl]-N-(2-chloro-4-sulfamoylphenyl)acetamide
TABLE-US-00004 [0071] Materials Amount Mol. Wt. mmoles thiotriazole
carboxylic acid 884 mg 404.28 2.2 4-amino-3- 452 mg 206.65 2.2
chlorophenylsulfonamide 22 ml (10 ml/mmol) pyridine phosphorus
oxychloride 0.24 ml 153.33 2.6 (1.2 eq)
Procedure:
[0072] To a solution of the carboxylic acid and aniline shown
above, in pyridine at 0.degree. C., was added POCl.sub.3 dropwise
for 5 min. The reaction was complete after stirring at 0.degree. C.
for an additional 50 min. The reaction mixture was quenched by
addition of H.sub.2O (1 mL), then concentrated in vacuo to light
brown oil which was diluted with CH.sub.2Cl.sub.2 (200 ml). The
organic layer was washed with H.sub.2O (1.times.50 ml), saturated
NaHCO.sub.3 solution (1.times.50 ml), then brine (1.times.50 ml).
The organic solution was dried over Na.sub.2SO.sub.4 and
concentrated to dryness. The resulting oil was triturated with EtOH
to give light yellow solid. To the mixture was added H.sub.2O to
collect more solid. The light yellow solid was collected by vacuum
filtration and dried under high vacuum for 16 hrs to yield 930 mg
(72%) of product. Additional product (132 mg, 10%) was recovered by
extraction of the filtrate with CH.sub.2Cl.sub.2 followed by column
chromatography with acetone/CH.sub.2Cl.sub.2 (20:80).
2-[5-Bromo-4-(4-cyclopropyl-7-methoxynaphthalen-1-yl)-4H-[1,2,4]-triazole--
3-ylsulfanyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide
##STR00017##
[0073] 1-amino-4-cyclopropyl-7-methoxynaphthalene
[0074] To a stirred solution of 8-amino-2-naphthol (5 g, 31.4 mmol)
in a mixture of tetrahydrofuran (50 mL) and dichloromethane (100
mL) was added di-t-butyldicarbonate (6.86 g, 31.4 mmol). The
mixture was stirred at 70.degree. C. for 18 hours. After the
mixture was cooled to room temperature, saturated aqueous sodium
carbonate was added and the product was extracted with
dichloromethane. The organic layer was washed with water and brine,
dried over sodium sulfate, filtered and concentrated under reduced
pressure. The obtained residue was purified by silica gel column
chromatography (dichloromethane:ethyl acetate, 9:1) to afford the
N--BOC derivative a. (4.85 g, 60% yield)
[0075] To a mixture of the N--BOC derivative a (4.85 g, 18.7 mmol)
and triethylamine (3.91, 28.1 mmol) in dichloromethane (170 mL) was
added methanesulfonic anhydride (3.58 g, 20.6 mmol) at 0.degree. C.
The mixture was stirred for 30 min and poured into saturated
aqueous sodium bicarbonate solution. The organic layer was
extracted with dichloromethane, dried over sodium sulfate, filtered
and concentrated under reduced pressure to give the
methanesulfonate ester b. (6.22 g, quantitative yield)
[0076] To a solution of methanesulfonate b (6.12 g, 18.1 mmol) in
150 mL of acetic acid was added N-bromosuccinimide (3.39 g, 19
mmol). The mixture was stirred for 2 h and water and
dichloromethane were added. The aqueous layer was adjusted to pH 7
by addition of 10 N aqueous sodium hydroxide. The organic layer was
extracted with dichloromethane, dried over sodium sulfate, filtered
and concentrated under reduced pressure to give the crude 5-bromo
derivative c. (7.6 g, quantitative yield)
[0077] A mixture of c (7.72 g, 18.5 mmol) and 10% aqueous sodium
hydroxide solution (370 mL) in tetrahydrofuran (220 mL) was stirred
at 50.degree. C. for 5 days. The mixture was cooled to 0.degree. C.
and neutralized with concentrated hydrochloric acid. The mixture
was concentrated under reduced pressure, and the product was
extracted with ethyl acetate. The organic layer was dried over
sodium sulfate, filtered and concentrated to give the naphthol d.
(5.87 g, 94% yield)
[0078] A mixture of naphthol d (3.53 g, 10.4 mmol), methyl iodide
(0.65 mL, 10.4 mmol) and sodium hydroxide (417 mg, 10.4 mmol) in
acetone (25 mL) was stirred at room temperature for 4 hours. The
resulting mixture was concentrated and the residue purified by
column chromatography (85% hexane/15% ethyl acetate) to afford 2.39
g, 65% yield of the methyl ether e.
[0079] A mixture of methyl ether e (3.25 g, 9.22 mmol) in 4N HCl in
1,4-dioxane (92 mL) was stirred at room temperature for 1 hour. The
mixture was concentrated under reduced pressure and was added ethyl
acetate and saturated sodium bicarbonate solution. The extracted
organic layer was washed with water and brine, dried over sodium
sulfate and concentrated under reduced pressure to give
2-methoxy-5-bromo-8-aminonaphthalene f (2.14 g, 92% yield)
[0080] To a solution of aminonaphthalene f (1 g, 4.0 mmol),
cyclopropyl boronic acid (438 mg, 5.1 mmol), potassium phosphate
(2.97 g, 14 mmol) and tricyclohexylphosphine (112 mg, 0.4 mmol) in
toluene (21 mL) and water (0.8 mL) under nitrogen atmosphere was
added palladium acetate (45 mg, 0.2 mmol) with vigorous stirring.
The mixture was heated to 100.degree. C. for 3 h and then cooled to
room temperature. Water was added and the mixture extracted with
ethyl acetate, dried over sodium sulfate and concentrated.
Purification by column chromatography (50% hexane/50% ethyl
acetate) afforded the title compound g. (699 mg, 82% yield)
##STR00018##
[0081] Compound g (699 mg, 3.28 mmol) was dissolved in 18 mL of
dichloromethane. Sodium bicarbonate (9 mL, sat. solution) and
thiophosgene (0.25 mL, 3.28 mmol) were added and the mixture
stirred at room temperature for 1 h. The organic layer was
separated, dried over sodium sulfate and concentrated to afford 819
mg, 98% yield of compound h which was used in the next step without
further purification.
[0082] Compound h (819 mg, 3.21 mmol) was dissolved in 6 mL of
dimethylformamide, aminoguanidine hydrochloride salt (532 mg, 4.8
mmol) and diisopropyl ethylamine (0.84 mL, 4.8 mmol) were added,
and the mixture was stirred at 50.degree. C. for 18 hours. The
mixture was then concentrated and to the residue was added 2M
aqueous sodium hydroxide solution (10 mL). The mixture was stirred
at 50.degree. C. for 18 hours and then cooled to room temperature.
The resulting mixture was then neutralized with aqueous 1N HCl and
the precipitate collected to give compound i. (200 mg, 25%
yield)
[0083] Compounds i (63 mg, 0.2 mmol) and/(57 mg, 0.2 mmol) were
dissolved in DMF (2 mL) and potassium carbonate (30 mg, 0.2 mmol)
was added. The mixture was stirred at room temperature for 18
hours. Water was then added to the mixture and the precipitate
formed collected to give 70 mg (57%) of compound k.
[0084] Dichloroacetic acid (0.05 mL, 0.226 mmol) was added to a
mixture of compound k (63 mg, 0.113 mmol), benzyltriethyl ammonium
bromide (93 mg, 0.34 mmol) and sodium nitrite (156 mg, 2.26 mmol)
in dibromomethane (5 mL). The mixture was stirred at room
temperature for 18 hours in the dark. The reaction mixture was then
concentrated and the resulting residue was purified by prep. TLC
(95% dichloromethane/5% methanol) to afford 13.8 mg of the sulfonic
acid and 2 mg of title compound l.
2-[5-Bromo-4-(4-cyclopropyl-2-methylnaphthalen-1-yl)-4H-[1,2,4]-triazole-3-
-ylsulfanyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide
##STR00019##
[0086] To a stirred solution of 2-methyl-1-aminonaphthalene a (7.5
g, 47.7 mmol) in tetrahydrofuran (225 mL) was added
N-bromosuccinimide (10 g, 56.2 mmol) at 0.degree. C. The mixture
was stirred at room temperature for 4 hours. Water was added to the
mixture and the product was extracted with ethyl acetate. The
organic layer was washed with water and brine, dried over sodium
sulfate, filtered and concentrated under reduced pressure. The
resulting residue was purified by column chromatography (75%
hexane/25% ethyl acetate) to afford 4.73 g, 42% yield of compound
b.
[0087] To a solution of b (1 g, 4.24 mmol), cyclopropyl boronic
acid (472 mg, 5.5 mmol), potassium phosphate (3.14 g, 14.8 mmol)
and tricyclohexylphosphine (118 mg, 0.42 mmol) in toluene (22 mL)
and water (0.85 mL) under nitrogen atmosphere was added palladium
acetate (47 mg, 0.21 mmol). The mixture was heated to 100.degree.
C. for 3 h and then cooled to room temperature. Water was added and
the mixture extracted with ethyl acetate, dried over sodium sulfate
and concentrated. Purification by column chromatography (90%
hexane/10% ethyl acetate) afforded compound c. (728 mg, 87%
yield)
[0088] Compound c (728 mg, 3.7 mmol) was dissolved in 18 mL of
dichloromethane. Sodium bicarbonate (9 mL, sat. solution) and
thiophosgene (0.28 mL, 3.7 mmol) were added and the mixture stirred
at room temperature for 1 h. Then, the organic layer was separated,
dried over sodium sulfate and concentrated to afford 877 mg, 99%
yield of compound d which was used in the next step without further
purification.
[0089] Compound d (877 mg, 3.7 mmol) was dissolved in 6 mL of
dimethylformamide, aminoguanidine hydrochloride salt (608.5 mg, 5.5
mmol) and diisopropyl ethylamine (1.0 mL, 5.5 mmol) were added and
the mixture stirred at 50.degree. C. for 18 hours. The mixture was
concentrated and to the resulting residue was added 2M aqueous
sodium hydroxide solution (15 mL). The mixture was stirred at
50.degree. C. for 18 hours and then cooled to room temperature. The
resulting mixture was then neutralized with aqueous 1N HCl and the
precipitate collected to give compound e. (472 mg, 50% yield)
[0090] Compounds e (100 mg, 0.34 mmol) and f (96 mg, 0.34 mmol)
were dissolved in DMF (2 mL) and potassium carbonate (51 mg, 0.37
mmol) was added. The mixture was stirred at room temperature for 18
hours. Water was then added to the mixture and the precipitate
formed collected and purified by prep. TLC (90% dichloromethane/10%
methanol) to give 83 mg, 45% yield of compound g.
[0091] Dichloroacetic acid (0.03 mL, 0.31 mmol) was added to a
mixture of compound g (83 mg, 0.15 mmol), benzyltriethyl ammonium
bromide (125 mg, 0.46 mmol) and sodium nitrite (211 mg, 3.06 mmol)
in dibromomethane (5 mL). The mixture was stirred at room
temperature for 18 hours in the dark. The reaction mixture was then
concentrated and the resulting residue was purified by prep. TLC
(95% dichloromethane/5% methanol) to afford 55.7 mg of the sulfonic
acid and 7 mg of title compound h.
2-[5-Bromo-4-(2-chloro-4-cyclopropylphenyl)-4H-[1,2,4]-triazole-3-ylsulfan-
yl]-N-(2-chloro-4-sulfamoylphenyl)acetamide
##STR00020## ##STR00021##
[0093] Compound a (1 g, 4.8 mmol) was dissolved in 10 mL of
anhydrous methylene chloride. To this mixture was added
triethylamine (0.68 mL, 4.8 mmol) and the reaction was stirred at
room temperature for 5 min. Acetyl chloride (0.5 mL, 7.2 mmol) was
then added at 0.degree. C. and the mixture stirred at room
temperature for 2 hours. Water and dichloromethane were added and
the layers separated. The organic layer was then dried over sodium
sulfate and concentrated to give 1.11 g, 92% yield of compound
b.
[0094] To a solution of b (500 mg, 2.01 mmol), cyclopropyl boronic
acid (225 mg, 2.62 mmol), potassium phosphate (1.49 g, 7.04 mmol)
and tricyclohexylphosphine (56 mg, 0.2 mmol) in toluene (10 mL) and
water (0.4 mL) under nitrogen atmosphere was added palladium
acetate (23 mg, 0.1 mmol). The mixture was heated to 100.degree. C.
for 3 h and then cooled to room temperature. Water was added and
the mixture extracted with ethyl acetate, dried over sodium sulfate
and concentrated to give 550 mg of crude product c that was used in
the next step without further purification.
[0095] Compound c (500 mg, 2.4 mmol) was dissolved in 4 mL of
ethanol. Aqueous 1N HCl (4 mL) was added and the mixture stirred at
reflux for 8 hours. The solvent was removed in vacuo to afford 440
mg of compound d which was used in the next step without further
purification.
[0096] Compound d (440 mg, 2.6 mmol) was dissolved in 14 mL of
dichloromethane. Sodium bicarbonate (7 mL, sat. solution) and
thiophosgene (0.2 mL, 2.6 mmol) were added and the mixture stirred
at room temperature for 1 h. Then, the organic layer was separated,
dried over sodium sulfate and concentrated to afford 877 mg, 99%
yield of compound e which was used in the next step without further
purification.
[0097] Compound e (447 mg, 2.1 mmol) was dissolved in 3 mL of
dimethylformamide, aminoguanidine hydrochloride salt (355 mg, 3.2
mmol) and diisopropyl ethylamine (0.56 mL, 3.2 mmol) were added and
the mixture stirred at 50.degree. C. for 18 hours. The mixture was
then concentrated and to the resulting residue was added 2M aqueous
sodium hydroxide solution (10 mL). The mixture was stirred at
50.degree. C. for 18 hours and then cooled to room temperature. The
resulting mixture was then neutralized with aqueous 1N HCl and the
precipitate (product) collected to give compound f (240 mg, 44%
yield)
[0098] Compounds f (89 mg, 0.33 mmol) and g (94 mg, 0.33 mmol) were
dissolved in DMF (1.5 mL) and potassium carbonate (51 mg, 0.37
mmol) was added. The mixture was stirred at room temperature for 18
hours. Water was then added to the mixture and the precipitate
formed collected and purified by prep. TLC (90% dichloromethane/10%
methanol) to give 116 mg, 68% yield of compound h.
[0099] Dichloroacetic acid (0.04 mL, 0.46 mmol) was added to a
mixture of compound h (116 mg, 0.23 mmol), benzyltriethyl ammonium
bromide (183 mg, 0.68 mmol) and sodium nitrite (304 mg, 4.6 mmol)
in dibromomethane (5 mL). The mixture was stirred at room
temperature for 18 hours in the dark. The reaction mixture was then
concentrated and the resulting residue was purified by prep. TLC
(95% dichloromethane/5% methanol) to afford 99.10 mg of the
sulfonic acid and 17.90 mg of title compound i.
4-(2-(5-bromo-4-(2-chloro-4-cyclopropyl-6-methylphenyl)-4H-1,2,4-triazol-3-
-ylthio)acetamido)-3-chlorobenzoic acid
##STR00022##
[0101] To a solution of 1 (1 g, 4.5 mmol), cyclopropyl boronic acid
(506 mg, 5.9 mmol), potassium phosphate (3.34 g, 15.8 mmol) and
tricyclohexylphosphine (126 mg, 0.45 mmol) in toluene (20 mL) and
water (0.76 mL) under nitrogen atmosphere was added palladium
acetate (51 mg, 0.23 mmol). The mixture was heated to 100.degree.
C. for 3 h and then cooled to room temperature. Water was added and
the mixture extracted with ethyl acetate, dried over sodium sulfate
and concentrated to give 775 mg of crude
2-chloro-4-cyclopropyl-6-methylbenzenamine (2) that was used in the
next step without further purification.
[0102] Compound 2 (775 mg, 4.3 mmol) was dissolved in 9 mL of
dichloromethane. Sodium bicarbonate (4.5 mL, sat. solution) and
thiophosgene (0.33 mL, 4.3 mmol) were added and the mixture stirred
at room temperature for 1 h. Then, the organic layer was separated,
dried over sodium sulfate and concentrated to afford 935 mg of
1-chloro-5-cyclopropyl-2-isothiocyanato-3-methylbenzene (3) which
was used in the next step without further purification.
[0103] Compound 3 (935 mg, 4.2 mmol) was dissolved in 5 mL of
dimethylformamide, aminoguanidine hydrochloride salt (695 mg, 6.3
mmol) and diisopropyl ethylamine (1.1 mL, 6.3 mmol) were added and
the mixture stirred at 50.degree. C. for 18 hours. The mixture was
then concentrated and to the resulting residue was added 2M aqueous
sodium hydroxide solution (20 mL). The mixture was stirred at
50.degree. C. for 18 hours and then cooled to room temperature. The
resulting mixture was then neutralized with aqueous 1N HCl and the
precipitate (product) collected to give
5-amino-4-(2-chloro-4-cyclopropyl-6-methylphenyl)-4H-1,2,4-triazo-
le-3-thiol (4). (780 mg, 66% yield)
[0104] Compound 4 (100 mg, 0.36 mmol) and
3-chloro-4-(2-chloroacetamido)benzoic acid (5) (88 mg, 0.36 mmol)
were dissolved in DMF (2 mL) and the mixture was stirred at
50.degree. C. for 18 hours. Water was then added and the mixture
extracted with ethyl acetate. The organic layer was separated,
dried over sodium sulfate and concentrated to give 192 mg, of crude
4-(2-(5-amino-4-(2-chloro-4-cyclopropyl-6-methylphenyl)-4H-1,2,4-triazol--
3-ylthio)acetamido)-3-chlorobenzoic acid (6) which was used in next
step without further purification.
[0105] Dichloroacetic acid (0.065 mL, 0.78 mmol) was added to a
mixture of compound 6 (192 mg, 0.39 mmol), benzyltriethyl ammonium
bromide (318 mg, 1.17 mmol) and sodium nitrite (538 mg, 7.8 mmol)
in dibromomethane (10 mL). The mixture was stirred at room
temperature for 18 hours in the dark. The reaction mixture was then
concentrated and the resulting residue was purified by prep. TLC
(95% dichloromethane/5% methanol) to afford 88 mg, 42% yield of
4-(2-(5-bromo-4-(2-chloro-4-cyclopropyl-6-methylphenyl)-4H-1,2,4-triazol--
3-ylthio)acetamido)-3-chlorobenzoic acid (7).
4-(2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)a-
cetamido)-3-chlorobenzoic acid
##STR00023##
[0107] To a solution of 1 (500 mg, 2.01 mmol), cyclopropyl boronic
acid (225 mg, 2.62 mmol), potassium phosphate (1.49 g, 7.04 mmol)
and tricyclohexylphosphine (56 mg, 0.2 mmol) in toluene (10 mL) and
water (0.4 mL) under nitrogen atmosphere was added palladium
acetate (23 mg, 0.1 mmol). The mixture was heated to 100.degree. C.
for 3 h and then cooled to room temperature. Water was added and
the mixture extracted with ethyl acetate, dried over sodium sulfate
and concentrated to give 550 mg of crude
4-cyclopropylnaphthalen-1-amine (2) that was used in the next step
without further purification.
[0108] Compound 2 (440 mg, 2.6 mmol) was dissolved in 14 mL of
dichloromethane. Sodium bicarbonate (7 mL, sat. solution) and
thiophosgene (0.2 mL, 2.6 mmol) were added and the mixture stirred
at room temperature for 1 h. Then, the organic layer was separated,
dried over sodium sulfate and concentrated to afford 877 mg, 99%
yield of 1-cyclopropyl-4-isothiocyanatonaphthalene (3) which was
used in the next step without further purification
[0109] Compound 3 (447 mg, 2.1 mmol) was dissolved in 3 mL of
dimethylformamide, aminoguanidine hydrochloride salt (355 mg, 3.2
mmol) and diisopropyl ethylamine (0.56 mL, 3.2 mmol) were added and
the mixture stirred at 50.degree. C. for 18 hours. The mixture was
then concentrated and to the resulting residue was added 2M aqueous
sodium hydroxide solution (10 mL). The mixture was stirred at
50.degree. C. for 18 hours and then cooled to room temperature. The
resulting mixture was then neutralized with aqueous 1N HCl and the
precipitate (product) collected to give
5-amino-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazole-3-thio-
l (4). (240 mg, 44% yield)
[0110] Compound 4 (789 mg, 2.79 mmol) and
3-chloro-4-(2-chloroacetamido)benzoic acid (5) (693 mg, 2.79 mmol)
were dissolved in DMF (6 mL) and the mixture was stirred at
50.degree. C. for 18 hours. Water was then added and the mixture
extracted with ethyl acetate. The organic layer was separated,
dried over sodium sulfate and concentrated to give 1.04 g, 75%
yield of
4-(2-(5-amino-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)-
acetamido)-3-chlorobenzoic acid (6).
[0111] Dichloroacetic acid (0.35 mL, 4.2 mmol) was added to a
mixture of compound 6 (1.04 g, 2.1 mmol), benzyltriethyl ammonium
bromide (1.65 g, 6.1 mmol) and sodium nitrite (2.9 g, 42.1 mmol) in
dibromomethane (44 mL). The mixture was stirred at room temperature
for 18 hours in the dark. The reaction mixture was then
concentrated and the resulting residue was purified by column
chromatography (95% dichloromethane/5% methanol) to afford 393 mg,
34% yield of
4-(2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)-
acetamido)-3-chlorobenzoic acid (7).
4-(2-(5-bromo-4-(7-methoxy-4-methylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylt-
hio)acetamido)-3-chlorobenzoic acid
##STR00024## ##STR00025##
[0113] A mixture of 8-amino-2-naphthol 1 (8.2 g, 52 mmol),
benzaldehyde (16 mL, 156 mmol) and sodium sulfate (41.3 g, 291
mmol) in THF (100 mL) was stirred at reflux over night. The mixture
was cooled to room temperature, filtered and concentrated under
reduced pressure. The resulting residue was purified by column
chromatography (hexane/ethyl acetate/triethyl amine 75/23/2) to
give 12.65 g of impure (E)-8-(benzylideneamino) naphthalen-2-ol (2)
which was used in the next step without further purification.
[0114] A mixture of 2 (12.65 g, 51.2 mmol), MeI (6.4 mL, 102 mmol)
and NaOH (6.14 g, 153 mmol) in acetone (125 mL) was stirred at room
temperature for 2 hours. The resulting mixture was concentrated and
the residue dissolved in ether, washed with water and brine and
concentrated. The resulting residue was dissolved in 2N HCl-THF
(780 mL, 2:1) and stirred at room temperature for 1.5 hrs. The
resulting solution was washed with ether, the aqueous layer
basified with Na2CO3 and extracted with ether. The organic layer
was washed with brine, dried over sodium sulfate and concentrated.
The resulting residue was purified by column chromatography
(Hex/EtOAc 3:1) to give 6.94 g, 78% yield of
7-methoxynaphthalen-1-amine (3).
[0115] To a stirred mixture of 3 (6.94 g, 40 mmol) and potassium
carbonate (16.6 g, 120 mmol) in acetone (100 mL) was added benzyl
bromide (19.0 mL, 160 mmol) at 0.degree. C. The mixture was
refluxed for 3 days and cooled to room temperature. The precipitate
removed and the filtrate concentrated. The resulting residue was
purified by column chromatography (Hex 100%) to remove the
unreacted benzyl bromide and then with ethyl acetate (100%) to give
11.75 g, 83% yield of N,N-dibenzyl-7-methoxynaphthalen-1-amine
(4).
[0116] To a stirred solution of DMF (30 mL) was added POCl.sub.3
(10.65 mL, 116 mmol) over 30 minutes at 0.degree. C. The mixture
was then stirred at 0.degree. C. for 30 minutes and added 4 (11.75
g, 33.2 mmol) in DMF (120 mL). The mixture was stirred at room
temperature for six days and the poured into ice-water. The product
mixture was extracted with dichloromethane and the organic layer
washed with water, aqueous sodium bicarbonate and brine, dried over
sodium sulfate and concentrated to afford 13.58 g of
4-(dibenzylamino)-6-methoxy-1-naphthaldehyde (5) which was used in
next step without further purification.
[0117] A mixture of 5 (5.0 g, 13.1 mmol) and Pd/Carbon (812 mg) in
methanol (150 mL) was stirred under hydrogen atmosphere (40 PSI)
for 18 hours. The mixture was passed through celite and
concentrated. The resulting residue was purified by column
chromatography (Hex/EtOAC 3:1) to give 826 mg, 35% yield of
7-methoxy-4-methylnaphthalen-1-amine (6).
[0118] Compound 6 (826 mg, 4.4 mmol) was dissolved in 25 mL of
dichloromethane. Sodium bicarbonate (15 mL, sat. solution) and
thiophosgene (0.34 mL, 4.4 mmol) were added and the mixture stirred
at room temperature for 1 h. Then, the organic layer was separated,
dried over sodium sulfate and concentrated to afford 1.9 g, 99%
yield of 4-isothiocyanato-6-methoxy-1-methylnaphthalene (7) which
was used in the next step without further purification
[0119] Compound 7 (1.0 g, 4.4 mmol) was dissolved in 10 mL of
dimethylformamide, aminoguanidine hydrochloride salt (723 mg, 6.5
mmol) and diisopropyl ethylamine (1.14 mL, 6.5 mmol) were added and
the mixture stirred at 50.degree. C. for 18 hours. The mixture was
then concentrated and to the resulting residue was added 2M aqueous
sodium hydroxide solution (10 mL). The mixture was stirred at
50.degree. C. for 18 hours and then cooled to room temperature. The
resulting mixture was then neutralized with aqueous 1N HCl and the
precipitate (product) collected to give
5-amino-4-(7-methoxy-4-methylnaphthalen-1-yl)-4H-1,2,4-triazole-3-
-thiol (8). (1.14 mg, 91% yield)
[0120] Compound 8 (200 mg, 0.7 mmol) and
3-chloro-4-(2-chloroacetamido)benzoic acid (9) (174 mg, 0.7 mmol)
were dissolved in DMF (3 mL) and the mixture was stirred at
50.degree. C. for 18 hours. Water was then added and the mixture
extracted with ethyl acetate. The organic layer was separated,
dried over sodium sulfate and concentrated to give 304 mg of
4-(2-(5-amino-4-(7-methoxy-4-methylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl-
thio)acetamido)-3-chlorobenzoic acid (10) which was used in the
next step without further purification.
[0121] Dichloroacetic acid (0.1 mL, 1.2 mmol) was added to a
mixture of compound 10 (304 mg, 0.6 mmol), benzyltriethyl ammonium
bromide (492 mg, 1.8 mmol) and sodium nitrite (828 mg, 12 mmol) in
dibromomethane (10 mL). The mixture was stirred at room temperature
for 18 hours in the dark. The reaction mixture was then
concentrated and the resulting residue was purified by column
chromatography (95% dichloromethane/5% methanol) to afford 80 mg,
24% yield of
4-(2-(5-bromo-4-(7-methoxy-4-methylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl-
tmo)acetamido)-3-chlorobenzoic acid (11).
2-[5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfanyl-
]-N-(2-chloro-4-N-propionylsulfamoylphenyl)acetamide
##STR00026##
[0123] A 50 mL round-bottomed flask was charged with
2-[5-bromo-4-(4-cyclopropyl-naphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfan-
yl]-N-(2-chloro-4-sulfamoylphenyl)-acetamide (45 mg, 0.076 mmol),
EDC (29 mg, 0.15 mmol), and propionic acid (6.7 .mu.L, 0.09 mmol)
in the mixture of 5 mL THF and 5 mL methylene chloride. To the
mixture was added DMAP (18.3 mg, 0.15 mmol) in one portion. The
reaction mixture was stirred at RT for 14 h. The solvents were
evaporated under reduced pressure yielding thick oily residue. The
residue was redissolved in 20 mL methylene chloride, then it was
washed with 20 mL 2.0 M aq. HCl solution. The organic layer was
dried over Na2SO4. The solvent was removed by a rotavapor yielding
oily residue. The residue was purified by silica-gel column
chromatography with a mixture of methanol and methylene chloride
(1:9). 18.5 mg (38%) of the desired product was obtained as white
solids.
2-[5-Bromo-4-(4-cyclopropyl-naphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfany-
l]-N-(2-chloro-4-propionylsulfamoyl-phenyl)lysinamide
##STR00027##
[0125] A 25 mL round-bottomed flask was charged with
2-[5-bromo-4-(4-cyclopropyl-naphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfan-
yl]-N-(2-chloro-4-sulfamoylphenyl)acetamide (50 mg, 0.085 mmol),
EDC (35 mg, 0.18 mmol), Boc-Lys(Boc)-OH DCHA (47 mg, 0.09 mmol) in
the mixture of 5 mL THF and 5 mL methylene chloride. To the mixture
was added DMAP (16 mg, 0.13 mmol) in one portion. The reaction
mixture was stirred at RT for 14 h. The solvents were evaporated
under reduced pressure yielding thick oily residue. The residue was
dissolved in 5 mL 4.0 M HCl in dioxane. The reaction was stirred at
RT for 14 h. The solvent was evaporated under reduced pressure
yielding thick oily residue. The residue was washed successively
with 10 mL methylene chloride and 10 mL ether yielding the title
compound as a light yellow solid (44 mg, 65%).
Reagents
1-Methyl-4-nitro-naphthalene
##STR00028##
[0127] To 1-methylnaphthalene (8.0 g, 56 mmol) in round bottom
flask at 0.degree. C. was added nitric acid (26 mL) dropwise.
(NOTE: A slow addition of nitric acid is most important to avoid
the formation of the other regioisomers). After the reaction
mixture was stirred for an additional 15 min at 0.degree. C., it
was poured into 65 mL of H.sub.2O. The aqueous solution was
extracted with benzene twice and the combined benzene solution was
washed with 10% NaOH solution, dried with Na.sub.2SO.sub.4, and
concentrated. Silica gel chromatography (EtOAc:Hexanes=5:95) gave
product still containing a few percentage of the other regioisomer.
It was recrystallized with EtOAc/Hexanes to give 9.0 g (43%) of
1.
4-Methyl-naphthalen-1-ylamine
##STR00029##
[0129] To a solution of 1-methyl-4-nitro-naphthyl-amine (4.0 g, 21
mmol) in ethanol (300 mL) was added Raney-Nickel (4 scoops). The
mixture was stirred under H.sub.2 (1 atm) for 16 h. The reaction
was filtered through a pad of Celite and concentrated. Purification
by silica gel flash column chromatography (EtOAc:Hexanes=15:85)
provided product (3.2 g, 75%).
4-Ethyl-5,6,7,8-tetrahydro-naphthalen-1-ylamine
##STR00030##
[0131] The procedure was essentially identical to the route for
4-Methyl-naphthalen-1-ylamine as described above, however, started
with a solution of 5-ethyl-8-nitro-1,2,3,4-tetrahydro-naphthalene
(795 mg, 3.95 mmol).
4-Methyl-naphthalen-1-yl-thiosemicarbazide
##STR00031##
[0133] To a solution of thiophosgene (0.33 mL, 4.3 mmol) in
anhydrous methylene chloride (5 mL) at 0.degree. C. was added
dropwise a solution of 4-methyl naphthyl amine (671 mg, 4.3 mmol)
and diisopropylethyl amine (1.5 mL, 8.6 mmol) in anhydrous
methylene chloride (5 mL). After the reaction mixture was stirred
for an additional 10 min at 0.degree. C., it was washed with 1% HCl
solution and then H.sub.2O, dried with Na.sub.2SO.sub.4, and
concentrated to give dark brown oil. The oil was dissolved in
hexanes (15 mL) and the resulting brown slurry was filtered. The
filtrated was concentrated to give a pure thioisocyanate. To a
solution of the thioisocyanate in anhydrous acetonitrile (20 mL)
was added hydrazine (0.13 mL, 4.3 mmol) at RT. After stirring at RT
for 20 min, the mixture was concentrated. The resulting yellow oil
was triturated with EtOAc:Hexanes (1:1) to give (701 mg, 71% yield)
of product as an off-white solid.
5-Difluoromethyl-4-(4-methyl-naphthalen-1-yl)-4H-[1,2,4]trizole-3-thiol
##STR00032##
[0135] A solution of 4-methyl naphthyl thiosemicarbazide (180 mg,
0.78 mmol) in difluoroacetic acid (2 mL) was heated at 100.degree.
C. for 4 h. When the mixture was cooled to room temperature, white
solid crystallized out of reaction mixture. To collect more
products, 2 mL of hexanes was added to the mixture. Filtration gave
(179 mg, 79% yield) product as a white solid.
5-Fluoromethyl-4-(4-methyl-naphthalen-1-yl-4H-[1,2,4]trizole-3-thiol
##STR00033##
[0137] To a solution of 4-methyl-naphthlyl-thiosemicarbazide (158
mg, 0.68 mmol) in MeOH (10 mL) and 4.37 M NaOMe (0.23 mL, 1.02
mmol) was added ethyl fluoroacetate (0.13 mL, 1.37 mmol) and
stirred at room temperature for 17 h. The reaction mixture was
concentrated, added water and washed with diethyl ether. To the
aqueous layer, the pH was adjusted with HCl and filtered off
product as white solid in (78 mg, 42% yield). .sup.1H NMR (DMSO,
300 MHz) .delta. 14.26 (s, 1H), 8.14 (d, J=8.4 Hz, 1H), 7.67-7.52
(m, 4H), 7.26 (d, J=8.4 Hz, 1H), 5.20 (dd, J=12.0, 21.0 Hz, 1H),
5.03 (dd, J=12.0, 20.4 Hz5 1H), 2.74 (s, 3H).
2-[5-Difluoromethyl-4-(4-methyl-naphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsul-
fanyl]-N-(2-methyl-4-sulfamoyl-phenyl)-acetamide
##STR00034##
[0139] In a solution of
5-difluoromethyl-4-(4-methyl-naphthalen-1-yl)-4H-[1,2,4]triazole-3-thiol
(53 mg, 0.18 mmol), K.sub.2CO.sub.3 (27.0 mg, 0.20 mmol) in DMF
(1.5 mL) was added
2-methyl-N-(2-methyl-4-sulfamoyl-phenyl)-acetamide (47 mg, 0.18
mmol). The reaction mixture was stirred at room temperature for 16
h. Upon the completion of the reaction, H.sub.2O (4.0 mL) was added
to the reaction and stirred until precipitation occurred and
filtered off product (77.0 mg, 83% yield). .sup.1H NMR (DMSO, 300
MHz) .delta. 9.84 (broad s, 1H), 8.18 (d, J=8.0 Hz, 1H), 7.70-7.53
(m, 7H), 7.18 (t, J=51.5 Hz, 1H), 7.11 (d, J=8.0 Hz, 1H), 4.26 (s,
2H), 2.82 (s, 3H), 2.27 (s, 3H).
N-(2-Chloro-4-sulfamoyl-phenyl)-2-[5-difluoromethyl-4-(4-ethyl-5,6,7,8-tet-
rahydro-naphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfanyl]-acetamide
##STR00035##
[0141] In a solution of
5-difluoromethyl-4-(4-ethyl-5,6,7,8-tetrahydro-naphthalen-1-yl)-4H-[1,2,4-
]triazole-3-thiol (85 mg, 0.28 mmol), K.sub.2CO.sub.3 (41.8 mg,
0.30 mmol) in DMF (2.0 mL) was added
2-chloro-N-(2-methyl-4-sulfamoyl-phenyl)-acetamide (77.8 mg, 0.28
mmol). The reaction mixture was stirred at room temperature
overnight. Upon completion of the reaction, MeOH was added to the
reaction and stirred until precipitation occurred and filtered off
product (71.0 mg, 46% yield). .sup.1H NMR (DMSO, 300 MHz) .delta.
10.14 (s, 1H), 8.03 (d, J=8.1 Hz, 1H), 7.88 (d, J=2.4 Hz, 1H), 7.74
(dd, J=2.1, 8.4 Hz, 1H), 7.46 (broad s, 2H), 7.34-7.00 (m, 3H),
4.33 (apparent q, J=15.6 Hz, 2H), 2.71 (t, J=5.7 Hz, 2H), 2.62 (q,
J=7.5 Hz, 2H), 2.28-2.08 (m, 2H), 1.72-1.60 (m, 4H), 1.19 (t, J=7.5
Hz, 3H).
N-(2-Chloro-4-sulfamoyl-phenyl)-2-[5-difluoromethyl-4-(4-methyl-naphthalen-
-1-yl)-4H-[1,2,4]triazol-3-ylsulfanyl]-acetamide
##STR00036##
[0143] In a solution of
5-difluoromethyl-4-(4-methyl-naphthalen-1-yl)-4H-[1,2,4]triazole-3-thiol
(59 mg, 0.20 mmol), K.sub.2CO.sub.3 (30.0 mg, 0.22 mmol) in DMF
(1.5 mL) was added
2-chloro-N-(2-methyl-4-sulfamoyl-phenyl)-acetamide (57 mg, 0.20
mmol). The reaction mixture was stirred at room temperature for 16
h. Upon the completion of the reaction, H2O (4.0 mL) was added to
the reaction and stirred until precipitation occurred and filtered
off product (77.0 mg, 71% yield). .sup.1H NMR (DMSO, 300 MHz)
.delta. 10.11 (broad s, 1H), 8.18 (d, J=10.0 Hz, 1H), 8.01 (d,
J=10.0 Hz, 1H), 7.87 (s, 1H), 7.75-7.54 (m, 5H), 7.46 (broad s,
2H), 7.18 (t, J=50.0 Hz, 1H), 7.11 (d, J=10.0 Hz, 1H), 4.32 (s,
2H), 2.27 (s, 3H).
2-[5-Fluoromethyl-4-(4-methyl-naphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfa-
nyl]-N-(2-methyl-4-sulfamoyl-phenyl)-acetamide
##STR00037##
[0145] In a solution of
5-fluoromethyl-4-(4-methyl-naphthalen-1-yl)-4H-[1,2,4]triazole-3-thiol
(89 mg, 0.33 mmol), K.sub.2CO.sub.3 (50.0 mg, 0.36 mmol) in DMF
(2.0 mL) was added
2-chloro-N-(2-methyl-4-sulfamoyl-phenyl)-acetamide (87 mg, 0.33
mmol). The reaction mixture was stirred at room temperature for 16
h. Upon the completion of the reaction, H.sub.2O (2.0 mL) was added
to the reaction and stirred til precipitation occurred and
filtered. Purified by reverse phase HPLC resulted product as a
solid in (53.3 mg, 50% yield). .sup.1H NMR (DMSO, 300 MHz) .delta.
9.84 (broad s, 1H), 8.18 (d, J=8.4 Hz, 1H), 7.71-7.53 (m, 7H), 7.26
(s, 2H), 7.10 (d, J=8.7 Hz, 1H), 5.34 (dd, J=12.0, 27.3 Hz, 1H),
5.18 (dd, J=12.3, 26.4 Hz, 1H), 4.22 (s, 2H), 2.75 (s, 3H), 2.25
(s, 3H).
N-(2-Chloro-4-sulfamoyl-phenyl)-2-[5-fluoromethyl-4-(4-methyl-naphthalen-1-
-yl)-4H-[1,2,4]triazol-3-ylsulfanyl]-acetamide
##STR00038##
[0147] In a solution of
5-fluoromethyl-4-(4-methyl-naphthalen-1-yl)-4H-[1,2,4]triazole-3-thiol
(89 mg, 0.33 mmol), K.sub.2CO.sub.3 (50.0 mg, 0.36 mmol) in DMF
(2.0 mL) was added
2-chloro-N-(2-chloro-4-sulfamoyl-phenyl)-acetamide (93 mg, 0.33
mmol). The reaction mixture was stirred at room temperature for 16
h. Upon the completion of the reaction, H.sub.2O (2.0 mL) was added
to the reaction and stirred til precipitation occurred and filtered
to give solid (126.8 mg, 74% yield). .sup.1H NMR (DMSO, 300 MHz)
.delta. 10.12 (broad s, 1H), 8.18 (d, J=8.7 Hz, 1H), 8.04 (dd,
J=4.8, 8.7 Hz), 7.87 (s, 1H), 7.76-7.52 (m, 5H), 7.46 (s, 2H), 7.11
(d, J=8.7 Hz, 1H), 5.35 (dd, J=12.3, 26.7 Hz, 1H), 5.19 (dd,
J=11.7, 25.8 Hz, 1H), 4.26 (s, 2H), 2.75 (s, 3H).
N-(2-Chloro-4-sulfamoyl-phenyl)-2-[4-(4-ethyl-5,6,7,8-tetrahydro-naphthale-
n-1-yl)-5-fluoromethyl-4H-[1,2,4]triazol-3-ylsulfanyl]-acetamide
##STR00039##
[0149] In a solution of
4-(4-ethyl-5,6,7,8-tetrahydro-naphthalen-1-yl)-5-fluoromethyl-4H-[1,2,4]t-
riazole-3-thiol (85 mg, 0.29 mmol), K.sub.2CO.sub.3 (44.4 mg, 0.32
mmol) in DMF (2.0 mL) was added
2-chloro-N-(2-chloro-4-sulfamoyl-phenyl)-acetamide (82.6 mg, 0.29
mmol). The reaction mixture was stirred at room temperature for 16
h. Upon the completion of the reaction, H.sub.2O (2.0 mL) was added
to the reaction and stirred til precipitation occurred and filtered
to give solid (73.0 mg, 47% yield).
[0150] .sup.1H NMR (DMSO, 300 MHz) .delta. 10.15 (s, 1H), 8.05 (d,
J=8.4 Hz, 1H), 7.87 (s, 1H), 7.74 (d, J=8.4 Hz, 1H), 7.46 (s, 2H),
7.21-7.06 (m, 2H), 5.26 (d, J=48.0 Hz. 2H), 4.29 (apparent q,
J=15.6 Hz, 2H), 2.71-2.58 (m, 3H), 2.25 (s, 1H), 2.25-2.09 (m, 2H),
1.72-1.59 (m, 4H), 1.19 (t, J=7.5 Hz, 3H).
[0151] Using the appropriate starting materials, the following
compounds are prepared by procedures analogous to the methods
disclosed above: [0152]
2-[5-Bromo-4-(2-chloro-4-(cyclopropylmethyl)phenyl)-4H-[1,2,4]-tri-
azole-3-ylsulfanyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide [0153]
2-[5-Bromo-4-(2-chloro-4-cyclobutylphenyl)-4H-[1,2,4]-triazole-3-ylsulfan-
yl]-N-(2-chloro-4-sulfamoylphenyl)acetamide [0154]
2-[5-Bromo-4-(2-chloro-4-(cyclopropylmethyl)naphthalen-1-yl)-4H-[1,2,4]-t-
riazole-3-ylsulfanyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide
[0155]
2-[5-Bromo-4-(2-chloro-4-cyclopropylphenyl)-4H-[1,2,4]-triazole-3-ylsulfa-
nyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide [0156]
2-[5-Trifluoromethyl-4-(2-chloro-4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]-
-triazole-3-ylsulfanyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide
[0157]
2-[5-Bromo-4-(4-cyclopropyl-5,6,7,8-tetrahydronaphthalen-1-yl)-4H-[1,2,4]-
-triazole-3-ylsulfanyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide
[0158]
2-[5-Bromo-4-(4-ethylnaphthalen-1-yl)-4H-[1,2,4]-triazole-3-ylsulfanyl]-N-
-(2-chloro-4-sulfamoylphenyl)acetamide [0159]
2-[5-Bromo-4-(4-ethyl-5,6,7,8-tetrahydronaphthalen-1-yl)-4H-[1,2,4]-triaz-
ole-3-ylsulfanyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide [0160]
2-[5-Bromo-4-(5-cyclopropylquinolin-8-yl)-4H-[1,2,4]-triazole-3-ylsulfany-
l]-N-(2-chloro-4-sulfamoylphenyl)acetamide [0161]
2-[5-Bromo-4-(5-cyclopropylisoquinolin-8-yl)-4H-[1,2,4]-triazole-3-ylsulf-
anyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide [0162]
2-[5-Bromo-4-(5-cyclopropylcinnolin-8-yl)-4H-[1,2,4]-triazole-3-ylsulfany-
l]-N-(2-chloro-4-sulfamoylphenyl)acetamide [0163]
2-[5-Bromo-4-(1-methylacenaphthene-5-yl)-4H-[1,2,4]-triazole-3-ylsulfanyl-
]-N-(2-chloro-4-sulfamoylphenyl)acetamide [0164]
2-[5-Bromo-4-(2-methylacenaphthene-5-yl)-4H-[1,2,4]-triazole-3-ylsulfanyl-
]-N-(2-chloro-4-sulfamoylphenyl)acetamide [0165]
2-[5-Bromo-4-(1,1-dimethylacenaphthene-5-yl)-4H-[1,2,4]-triazole-3-ylsulf-
anyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide
Inhibition of HIV-1 Reverse Transcriptase
[0166] Compounds were screened for inhibitory activity against
human immunodeficiency virus type 1 (HIV-1) using a high throughput
cell-based assay using HIV-1 expressing firefly luciferase as a
reporter gene and pseudotyped with vesicular stomatitis virus
envelope glycoprotein (VSV-G). Experimental procedures were
essentially as described by Connor et al. in Journal of Virology
(1996), 70: 5306-5311 (Characterization of the functional
properties of env genes from long-term survivors of human
immunodeficiency virus type 1 infection), and Popik et al. in
Journal of Virology (2002), 76: 4709-4722 (Human immunodeficiency
virus type 1 uses lipid raft-colocalized CD4 and chemokine
receptors for productive entry into CD4.sup.+ T cells). It should
be particularly appreciated that the virus contains two introduced
mutations in the RT gene (K103N and Y181C, created by PCR
mutagenesis) that render the virus highly resistant to current
non-nucleoside HIV-1 drugs. Virus stocks were generated by
cotransfection of plasmid DNA encoding VSV-G with vector
pNL4-3Env(-)Luc(+) into 293T cells. Sixty-four hours after
transfection, virus-containing medium was collected by
centrifugation and stored frozen at -80.degree. C.
[0167] HeLa cells were infected with the VSV-G pseudotyped virus in
the presence of screening compounds in a 384-well microtiter plate
format. Forty-eight hours after initial infection, lysis buffer and
Luciferase Assay Reagent (Promega) was added to the cells and
luciferase activity was determined by counting the resultant
luminescence using a LJL luminometer. Since the luciferase gene is
carried in the virus genome, its expression level directly reflects
the virus replication level in the presence of a compound.
[0168] To evaluate the activity of the compounds against wild type
HIV-1, a HeLa-JC53 cell line that expresses high levels of CD4 and
CCR5 was employed (Platt et al., Journal of Virology (1998), 72:
2855-2864: Effect of CCR5 and CD4 cell surface concentrations on
infection by macrophagetropic isolates of human immunodeficiency
virus type 1). The cell line was modified by isolation of a stable
cell line that expresses luciferase under the control of the HIV-1
promoter (long terminal repeat, i.e., LTR). HIV-1 infection of this
cell line stimulates the transcription of luciferase from the HIV-1
promoter and the luciferase gene expression level is proportional
to the level of virus replication (Harrington et al. in Journal of
Virology Methods (2000), 88: 111-115: Direct detection of infection
of HIV-1 in blood using a centrifugation-indicator cell assay; and
Roos et al. in Virology (2000), 273: 307-315: LuSIV cells: a
reporter cell line for the detection and quantitation of a single
cycle of HIV and SIV replication). Procedures for virus infection,
compound testing and luciferase activity determination were the
same as for the VSV-G pseudotyped HIV-1.
[0169] Two approaches were used to evaluate the cytotoxicity of the
positive compounds discovered in the HIV-1 virus assays. The first
approach employed another modified HeLa-JC53 cell line that
constitutively expresses high level of luciferase without virus
infection. The level of luciferase expression in these cells served
as an indicator for cell replication in the presence of the
compounds. Procedures for compound testing and luciferase activity
determination were the same as for the virus infection tests. The
other toxicity assay utilized HeLe-JC53 cells and a commercially
available MTS assay kit (Promega) that measures the mitochondria
function of the cells.
[0170] Using similar methods as described above,
2-[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfany-
l]-N-(2-methyl-4-sulfamoylphenyl)acetamide and
2-[5-bromo-4-(4-ethylnaphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(-
2-chloro-4-sulfamoylphenyl)-acetamide were synthesized, as were the
N-4-carbamyl analog,
2-[5-bromo-4-(4-ethyl-naphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfanyl]-N--
(2-chloro-4-carbamoylphenyl)-acetamide and the N-4-carboxyl analog.
Each of the compounds was tested against a panel of mutant HIV
reverse transcriptases, including 20 of the 22 of the mutants that
are found in about 2% or more of the patient samples that are
resistant to the most widely used non-nucleoside HIV-RT inhibitor
efavirenz
((4S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H--
3,1-benzoxazin-2-one). For each of the 20 high-prevalence mutants
tested, at least one of these compounds was more than 20 fold more
potent than efavirenz or showed EC.sub.50 of less than 1 nM. In
most cases both criteria were met. In the majority of cases all
three compounds were more potent than efavirenz. Compounds were
compared for activity on wild type, Y181C and Y188L mutant reverse
transcriptases. Both amides were significantly superior to the
carboxylic acid on all three enzymes.
Results
[0171] Compounds of the invention were tested against the wild-type
and four mutant HIV reverse transcriptases. The results are listed
in Table 1 as EC.sub.50 (nM) and IC.sub.50 (nM). In the Table, A
represents <50 nM, B is between 50 and 100 nM, and C is >100
nM. ND is not determined. Preferred compounds in this invention are
those that exhibit activities on wild-type (WT) and resistant
mutants below 50 nM in both EC.sub.50 and IC.sub.50.
##STR00040##
TABLE-US-00005 TABLE 1 IC.sub.50 EC.sub.50 EC.sub.50 EC.sub.50 WT
IC.sub.50 IC.sub.50 WT Y181C Y188L RT Y181C Y188L No. R.sub.1 A Ar
R.sub.2 (nM) (nM) (nM) (nM) (nM) (nM) 1 CF.sub.2H ##STR00041##
##STR00042## H C C C A C C 2 CF.sub.2H ##STR00043## ##STR00044## H
A A A A A C 3 CF.sub.2H ##STR00045## ##STR00046## H A B C A C C 4
CF.sub.2H ##STR00047## ##STR00048## H A A A A A C 5 CF.sub.2H
##STR00049## ##STR00050## H A C C A C C 6 Br ##STR00051##
##STR00052## H A A C A B C 7 Br ##STR00053## ##STR00054## H 8 Br
##STR00055## ##STR00056## H A A A A A C 9 Br ##STR00057##
##STR00058## H A A A 10 Br ##STR00059## ##STR00060## H A A A A A C
11 Br ##STR00061## ##STR00062## H A A A A A B 12 Br ##STR00063##
##STR00064## H A A A A A B 13 Br ##STR00065## ##STR00066## H A A A
A A C 14 CF.sub.2H ##STR00067## ##STR00068## H A A A A A C 15 Br
##STR00069## ##STR00070## H A B C A A B 16 CF.sub.3 ##STR00071##
##STR00072## H A B C A A C 17 CH.sub.2F ##STR00073## ##STR00074## H
A A C A A C 18 Br ##STR00075## ##STR00076## H A A A A A A 19 Br
##STR00077## ##STR00078## H B B C A A B 20 Br ##STR00079##
##STR00080## H C C C A A B 21 Br ##STR00081## ##STR00082## H B C C
A A C 22 Br ##STR00083## ##STR00084## H A A B A A B 23 Br
##STR00085## ##STR00086## H A A A A A C 24 Br ##STR00087##
##STR00088## H C C C A B C 25 Br ##STR00089## ##STR00090## H A A A
A A B 26 Br ##STR00091## ##STR00092## H A A A A A C 27 Br
##STR00093## ##STR00094## H A A C A B C 28 Br ##STR00095##
##STR00096## H A A A A A C 29 Br ##STR00097## ##STR00098## H A A C
A B C 30 Br ##STR00099## ##STR00100## H A A C A B C 31 Br
##STR00101## ##STR00102## H A A C A A C 32 Br ##STR00103##
##STR00104## H C C C C C C 33 Br ##STR00105## ##STR00106## H A A C
A A C 34 Br ##STR00107## ##STR00108## H A A A 35 Br ##STR00109##
##STR00110## H A A 36 CF.sub.2H ##STR00111## ##STR00112## H A A A A
A C 37 Br ##STR00113## ##STR00114## H A A A A A B 38 Br
##STR00115## ##STR00116## H A A A A A C 39 Br ##STR00117##
##STR00118## H A A A A A B 40 Br ##STR00119## ##STR00120## H A A A
A A C 41 CH.sub.3 ##STR00121## ##STR00122## H A A C A C C 42 Br
##STR00123## ##STR00124## H A A A A A C 43 CH.sub.3 ##STR00125##
##STR00126## H A A A A B C 44 CF.sub.2H ##STR00127## ##STR00128## H
A A A A A C 45 CH.sub.3 ##STR00129## ##STR00130## H A A B A C G 46
CH.sub.3 ##STR00131## ##STR00132## H A A A A B C 47 CF.sub.2H
##STR00133## ##STR00134## H A A A A A C 48 CF.sub.2H ##STR00135##
##STR00136## H A A B A A C 49 CFH.sub.2 ##STR00137## ##STR00138## H
A A C A B C 50 Br ##STR00139## ##STR00140## H A A A A A B 51
CF.sub.2H ##STR00141## ##STR00142## H A A A A A C 52 CFH.sub.2
##STR00143## ##STR00144## H A A A A C C 53 CFH.sub.2 ##STR00145##
##STR00146## H A A A A A C 54 CF.sub.2H ##STR00147## ##STR00148## H
A A B A A C 55 CFH.sub.2 ##STR00149## ##STR00150## H A A B B A C 56
CF.sub.2H ##STR00151## ##STR00152## H A A C A C C 57 CF.sub.2H
##STR00153## ##STR00154## H A A B A B C 58 CF.sub.2H ##STR00155##
##STR00156## H B C C A C C 59 CF.sub.2H ##STR00157## ##STR00158## H
C C C A C C 60 CF.sub.2H ##STR00159## ##STR00160## H C C C A C C 61
Br ##STR00161## ##STR00162## H A A A A A C 62 Br ##STR00163##
##STR00164## H A A C A C C 63 CF.sub.2H ##STR00165## ##STR00166## H
A A A A B C 64 CF.sub.2H ##STR00167## ##STR00168## H A A A A C C 65
CFH.sub.2 ##STR00169## ##STR00170## H A A B A C C 66 H ##STR00171##
##STR00172## H A A C A B C 67 CFH.sub.2 ##STR00173## ##STR00174## H
A A A A A C 68 CF.sub.2H ##STR00175## ##STR00176## H A A C A A C 69
CF.sub.2H ##STR00177## ##STR00178## H A A A A A B 70 I ##STR00179##
##STR00180## H A A A A B C 71 CF.sub.2H ##STR00181## ##STR00182## H
A A A A A C 72 Br ##STR00183## ##STR00184## H A A A A A B 73 Br
##STR00185## ##STR00186## H A A A A A B 74 Br ##STR00187##
##STR00188## H A A A A A B 75 Br ##STR00189## ##STR00190## H A A A
A A C 76 Br ##STR00191## ##STR00192## Me A B C A B C 77 Br
##STR00193## ##STR00194## H A B C A B C 78 Br ##STR00195##
##STR00196## H A A C A A C 79 Br ##STR00197## ##STR00198## H A A A
A A B 80 Br ##STR00199## ##STR00200## H A A A A A B 81 Br
##STR00201## ##STR00202## H A A A A A B 82 CFH.sub.2 ##STR00203##
##STR00204## H A A A A A C 83 CF.sub.3 ##STR00205## ##STR00206## H
A A A A B C 84 CF.sub.3 ##STR00207## ##STR00208## H A A A A C C 85
Br ##STR00209## ##STR00210## H A A A A A C 86 Br ##STR00211##
##STR00212## H A A A A A C 87 Br ##STR00213## ##STR00214## H A A A
A A B 88 Br ##STR00215## ##STR00216## H A A A A A C 89 Cl
##STR00217## ##STR00218## H A A A A A C 90 Br ##STR00219##
##STR00220## H A A B A A C 91 Br ##STR00221## ##STR00222## H A A A
A A B 92 Br ##STR00223## ##STR00224## H A A A A A B 93 Br
##STR00225## ##STR00226## H A A A A A C 94 Br ##STR00227##
##STR00228## H A A A A A C 95 Br ##STR00229## ##STR00230## H A A A
A A A 96 CF.sub.2H ##STR00231## ##STR00232## H A A C B C C 97
CF.sub.2H ##STR00233## ##STR00234## H ND ND ND C C C 98 Br
##STR00235## ##STR00236## H A A A A A B 99 CF.sub.2H ##STR00237##
##STR00238## H A A C A A C 100 CF.sub.2H ##STR00239## ##STR00240##
H A A A A B B 101 Br ##STR00241## ##STR00242## H A A A A B A 102 Br
##STR00243## ##STR00244## H A A A B A A 103 Br ##STR00245##
##STR00246## H A A B A A B 104 Br ##STR00247## ##STR00248## H A A A
A A A 105 Br ##STR00249## ##STR00250## H A A B A A C 106 Br
##STR00251## ##STR00252## H A C B B A C 107 Br ##STR00253##
##STR00254## H A A C A A B 108 Br ##STR00255## ##STR00256## H A A A
A A C 109 Br ##STR00257## ##STR00258## H A A A B A C 110 Br
##STR00259## ##STR00260## H A C C A A B 111 Br ##STR00261##
##STR00262## H B C C A A C 112 Br ##STR00263## ##STR00264## H A C C
A A C 113 Br ##STR00265## ##STR00266## H B B C A A B 114 Br
##STR00267## ##STR00268## H A A C B A B 115 Br ##STR00269##
##STR00270## H A A B A A B 116 Br ##STR00271## ##STR00272## H B C C
A A B 117 Br ##STR00273## ##STR00274## H A B C A A B 118 Br
##STR00275## ##STR00276## H A A A A A C 119 Br ##STR00277##
##STR00278## H A A A A A C 120 Br ##STR00279## ##STR00280## H A A A
A A C 121 Br ##STR00281## ##STR00282## H A A A B A C
122 Br ##STR00283## ##STR00284## H A A B A A C 123 Br ##STR00285##
##STR00286## H A A A A A C 124 Br ##STR00287## ##STR00288## H A A A
A A C 125 Br ##STR00289## ##STR00290## H A A A A B A 126 Br
##STR00291## ##STR00292## H A A A A A C 127 Br ##STR00293##
##STR00294## H A A A A A A 128 Br ##STR00295## ##STR00296## H A A A
A A B 129 Br ##STR00297## ##STR00298## H A A A A A A 130 Br
##STR00299## ##STR00300## H A A A A B B 131 Br ##STR00301##
##STR00302## H A A A A A C 132 Br ##STR00303## ##STR00304## H A A A
A A B 133 Br ##STR00305## ##STR00306## H A A A A A C 134 Br
##STR00307## ##STR00308## H A A A A A C 135 Br ##STR00309##
##STR00310## H A A C A B B 136 Br ##STR00311## ##STR00312## H A A A
A A B 137 Br ##STR00313## ##STR00314## H A A A A A A 138 Br
##STR00315## ##STR00316## H A A A A A C 139 Br ##STR00317##
##STR00318## H A A B C C C 140 Br ##STR00319## ##STR00320## H A A A
A A A 141 Br ##STR00321## ##STR00322## Me A A B C 142 Br
##STR00323## ##STR00324## Me A A C A A C
* * * * *